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Chronic allograft rejection (CR) is the main barrier to long-term transplant 
survival. CR is a progressive disease defined by interstitial fibrosis, vascular neointimal 
development, and graft dysfunction. The underlying mechanisms responsible for CR 
remain poorly defined, although transforming growth factor  (TGF has been strongly 
implicated in promoting fibrotic diseases and CR. However, TGFis a suppressive 
assessment of the fibrotic and anti-inflammatory activities of TGF in cardiac transplant 
was performed.  
In this study, the role of TGFβ on graft-reactive cellular and humoral responses, T 
regulatory cell (Treg) function, allograft acceptance and the progression of CR are 
assessed. These studies identify TGF dependent and independent pathways to allograft 
acceptance, and investigate the contribution of TGF-induced IL-17 in the progression of 
CR. Since TGFexhibits exacerbating or ameliorating characteristics depending on the 
site of action, TGF neutralization within the allograft addresses local TGF inhibition on 
fibrosis and graft-reactive T and B cell responses. Studies in this dissertation provide 
insight into the underlying causes of CR and identify therapeutic targets for treatment of 




Chapter 1: Introduction 
Following 50 years of pioneering work by multiple researchers in animal models 
of heart transplant(1-6), Christian Barnard performed the first successful human 
orthotopic heart transplant at Groote Schuur Hospital in Cape Town, South Africa on 
December 3, 1967 (1). The transplant recipient received an immunosuppressive cocktail 
of high dose prednisone, hydrocortisone, azathioprine, actinomycin C as well as local 
irradiation, and succumbed to pneumonia 18 days post-transplant (1). One year later, over 
100 cardiac transplants were performed in 17 countries with a mean survival rate of 29 
days (3). Most institutions abandoned the procedure by 1970 (2). However, experimental 
work that focused on immunsuppression, infection, donor management and surgical 
technique boosted the one-year survival rate from 22% to 65% between 1968 and 1978 
and resulted in a resurgence of interest in cardiac transplant (3). The introduction of the 
immunosuppressant, cyclosporine, in 1981, further improved the one-year survival rate to 
80% (4). As of 2008, the Registry of the International Society for Heart and Lung 
Transplantation calculated that over 81,000 transplants worldwide have been performed, 
with a one-year survival rate of 81% and a patient half-life (time to 50% survival) of 10 
years (5). Early mortality is due to primary graft failure, while chronic rejection (CR) is 




Prior to work performed by Sir Peter Medawar and colleagues, the mechanism by 
which a transplant recipient rejects an allograft was unknown (6). Medawar‟s initial work 
in a burn unit began to elucidate the role of the immune system in allograft rejection and 
methods of inducing tolerance (7). Medawar and Gibson performed serial biopsies and 
examined the skin graft histology from a severely burned woman who received both 
autografts and allografts (6, 7). Within a week, high numbers of infiltrating leukocytes 
were observed within the allografts and they were rejected. In contrast, the autografts 
remained normal, with minimal signs of inflammatory cell infiltration. A second set of 
skin grafts from the allogeneic donor underwent accelerated rejection, accompanied with 
a more intense inflammatory response, indicating a recall response. Medawar postulated 
that “…the mechanism by which foreign skin is eliminated belongs to the general 
category of actively acquired immune reactions” (7). The discovery of histocompatibility 
genes (8) and the realization that animals recognize their own tissues (“self”) and do not 
react against them while responding rapidly to foreign (“non-self”) stimuli (9), led 
Medawar to realize that genetic variations between donor and host resulted in differential 
immune responses toward transplants (10). This work fueled his interest in acquired 
tolerance, also referred to as the „Holy Grail,‟ which is “…a state in which an animal or 
even a patient can be made selectively unresponsive to the antigens of a given graft, 
while the remainder of the immune defense mechanisms remain intact” (3). As evidenced 
by the heart transplant statistics from the Registry in 2008, the Holy Grail of transplant 
tolerance has yet to be realized, requiring further refinements in our understanding of the 




1.1 T cells 
 Medawar and Gibson‟s skin graft experiment (7) demonstrated immunologic 
specificity of allograft rejection: donor-specific response, systemic immunity and 
immunologic memory. Most solid organ transplants do not occur between genetically 
identical individuals, so the major barrier to transplant acceptance is the recipient‟s 
immune system recognizing and responding to the genetic disparity in the major 
histocompatibility complex (MHC) (HLA in humans; H2 in mice) (11). T cells are the 
are the mediators of graft rejection (12). The importance of T cells in graft rejection is 
illustrated in transplanted mice that lack T cells, due to genetic mutation or neonatal 
thymectomy (13). These mice fail to reject grafts unless reconstituted with T cells. CD4+ 
T cells initiate this response following interactions with antigen presenting cells (APCs) 
by becoming activated and assuming effector functions (11). CD4+ T cells enhance the 
immune response toward an allograft by producing cytokines and aiding in the activation 
of alloreactive CD8+ T cells and B cells (12). In the absence of immunosuppressants, 
activated CD8+ T cells infiltrate cardiac allografts and mediate graft destruction during 
acute rejection (12). Conversely, CD4+ T cells can acutely reject allografts by mounting 
a Th2-dominant response characterized by an aggressive eosinophil infiltration (14). To 
make an effective immune response, however, T cells must be able to respond to their 
specific antigen and undergo activation and effector cell differentiation. The following 
four sections will review this process.  
1.2 T cell activation: signal one 
 Activation of a T cell is initiated by engagement of the T cell receptor (TCR)/CD3 




Figure 1: Initial steps in T cell activation. APCs, which express CD40, present Ag to the T 
cell receptor in the context of peptide-MHC. This is referred to as signal 1. Antigen recognition 
by the T cell induces CD40L expression. Stimulation of the APC through CD40 induces 
maturation, including IL-12 production and CD80/CD86 expression. CD80/CD86 delivers co-
stimulation to the T cell through CD28, which is signal 2. T cells proliferate and assume effector 
function. A CD28-related protein termed CTLA-4 is also induced on activated T cells and serves 
to deliver an inhibitory signal to dampen the proliferative response. CTLA-4 binds CD80/CD86 
with at least a log fold higher affinity than CD28. 
 
 
recognizes foreign antigen in the context of MHC molecules, and the sole function of the 
MHC molecule is to associate with peptides from “non-self” in order to present them on 
the cell surface for T cell recognition (11). There are two groups of MHC loci involved in 
antigen presentation: Class I and Class II (reviewed in (15)). MHC I molecules are 
composed of a 45 kDa heavy chain, comprised of the 1, 2 and 3 domain and the non-
covalently associated light 2-microglobulin (2m) (16, 17). Class I molecules associate 
with peptides derived from the cytosol and are presented on the surface of most cells and 
tissues to facilitate efficient immune surveillance by CD8+ T cells (18). These peptides 
are short (8-11 amino acid in length) created by the proteasome and trimmed by 




and  chain, which form a heterodimeric glycoprotein. The length of the peptides are 
typically larger, between 12-19 amino acids long, and are derived from extracellular 
sources, endosomes and lysosomes (15). MHC class II is restricted to APCs, such as 
dendritic cells (DCs), macrophages, and B cells (20).  
The cell surface co-receptors of T cells, CD4 and CD8, are necessary for an 
effective immune response toward antigen. CD8 is expressed by CD8+ T cells, which can 
produce cytokines and differentiate into cytotoxic T cells and directly kill cells, while 
CD4 is expressed by  T “helper” cells (Th), whose primary function is to activate 
additional cells, such as B cells and CD8+ T cells (12). During antigen recognition, the 
CD4 and CD8 molecules associate with the TCR on the T cell and bind to conserved 
sequence on the MHC portion of the peptide:MHC complex, away from the peptide-
binding site. The CD4 molecule on T cells binds to MHC II and the CD8 molecule binds 
to MHC I (20). The differential expression of CD4 and CD8 on T cells dictates the nature 
of the antigens to which these cells respond.           
 There are multiple pathways in which antigen recognition can occur in the 
transplant setting (11). In the direct allorecognition pathway, recipient T cells can 
recognize intact MHC alloantigens displayed on the surface of donor APCs (passenger 
leukocytes) that are carried within transplanted organs (21). These passenger leukocytes 
migrate from the graft into the recipient spleen and lymph nodes and activate T cells that 
are capable of cross-reacting. The indirect allorecognition pathway involves a self-MHC 
restricted response in which alloantigen shed by dying cells from the graft or passenger 




macrophages (22). Either of these pathways is capable of providing the first signal of 
activation to alloreactive T cells. 
1.3 Allorecognition 
 The strength of a T cell response provoked by MHC-incompatible cells is 
vigorous (23). This can be observed in vitro in a mixed lymphocyte reaction (MLR) (24) 
or in vivo in the rejection of solid organ transplants (reviewed in (11)). Polymorphisms at 
the MHC locus are referred to as alloantigens (20). MHC class I and II molecules are 
particularly polymorphic in the antigen-binding cleft, which creates a vast diversity in the 
number of potential T cell receptor binding sites (11). Alloreactivity refers to the 
stimulation of T cells by “non-self” MHC molecules, and can occur through either direct 
or indirect allorecognition (20).  
Direct Allorecognition 
 In direct allorecognition, a high frequency of recipient T cells can recognize intact 
MHC alloantigens displayed on the surface of donor APCs that are carried within 
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 or less for antigen specific self-MHC restricted 
cells (21, 23). This indicates that T cells in the recipient can react with self-MHC and 
peptide as well as cross-react with foreign MHC as a result of conserved sequences 
within the locus (25). In direct allorecognition, host T cells are primed by donor APCs 
that migrate from the graft into the spleen and draining lymph nodes of the recipient (23). 
T cells with receptors that cross-react with allogeneic class I and class II molecules, in 
combination with peptide, are activated and acquire effector function. Alloreactive CD8+ 




and initiate antibody (Ab) production by alloreactive B cells (12). Direct allorecognition 
is primarily responsible for acute rejection (22). 
Indirect Allorecognition 
 Indirect allorecognition comprises a second mechanism of alloreactivity that 
results in graft rejection (23). Indirect allorecognition is a self-MHC restricted response 
in which alloantigen shed from the graft by dying cells is processed and presented by 
recipient APCs (22). Peptides derived from foreign MHC molecules make up a 
significant source of polymorphic peptides that are recognized by recipient T cells. T 
cells (primarily CD4+)--activated through the indirect allorecognition pathway--
contribute to rejection by stimulating macrophages, which can induce graft injury (22). In 
addition, the indirect pathway plays an important role in the induction of a humoral 
response toward the graft. Indirect allorecognition is thought to contribute significantly to 
CR (26).              
1.4 T cell activation: signal 2 
 T cell activation was initially postulated to require only one signal (reviewed in 
(27)). However, investigations by Lafferty and Cunningham lead them to realize that a 
second signal—a co-stimulatory signal--was required for T cell activation and rapid 
expansion of T cells in response to antigen (27). There are a constellation of co-
stimulatory molecules that are crucial to drive clonal expansion, survival and T cell 
differentiation, including CD28:CD80 (B7-1)/CD86 (B7-2), OX40:OX40L, PD1/2:PD-






CD40 and its ligand, CD154 (CD40L), are members of the tumor necrosis factor 
receptor (TNFR) and TNF superfamily, respectively (28). Similar to many co-stimulatory 
molecules, CD40L is expressed only on a T cell following activation, while CD40 is 
expressed constitutively at a low level on APCs, but can be significantly upregulated 
upon activation. CD40 is expressed by B cells, macrophages, DCs, and endothelial cells 
(29). In addition, inflammatory cytokines can induce parenchymal cells, such as 
fibroblasts and endothelial cells, to express CD40 (30). CD40L is expressed on a variety 
of cells, including activated CD4+ and CD8+ T cells, natural killer (NK) cells, 
eosinophils and human platelets (29). The main effects of CD40:CD40L interaction is to 
prime and expand CD4+ T cells, activate APCs to upregulate co-stimulatory activity and 
cytokine production, induce B cell isotype switching, and stimulate macrophages and 
endothelial cells (31). 
 CD40 is a transmembrane protein with a cytoplasmic tail that contains two 
domains. The first domain associates with TNFR-associated (TRAF) binding, while the 
second domain independently activates NF-κB  (reviewed in (31)). In addition, a proline-
rich sequence in the intracellular membrane proximal region of CD40 interacts with 
Janus Kinase 3 (Jak3). Upon CD40L binding, CD40 forms a trimeric complex that 
activates NF-κB. Simultaneously, the intracellular region interacts with JAK/signal 
transducer and activator of transcription (STAT) pathway, as well as members of the 
TRAF family, which phosphorylates STAT3, releasing it to translocate into the nucleus 
to regulate gene transcription (31). B cell CD40 ligation induces proliferation and 




IgG (32). CD40 stimulation of macrophages induces these cells to produce nitric oxide 
and IL-12 to enhance macrophage cytotoxicity (33). CD40 ligation in DCs induces a 
prosurvival signal, upregulates CD80/CD86, enhances antigen presentation, and induces 
the secretion of TNF, IL-8, IL-12 and macrophage inflammatory protein -1 (MIP-1 
(31).  
 CD40L signaling has been demonstrated to activate jun N-terminal 
kinase/mitogen activated protein kinase (JNK/p38MAP kinase), sphinogmyelinase, and 
PKC, inducing the activation of NF-κB  (reviewed in (34)). However, the entire 
mechanism of action still remains to be elucidated. In addition to T cell priming, cross-
linking of CD40L induces the secretion of many cytokines including IL-4, IFN, IL-10 
and TNF(35). The importance of this co-stimulatory molecule in T cell activation was 
demonstrated in CD40L deficient mice, which exhibit a lack of T cell priming in 
response to antigen (36). In humans, CD40L dysfunction is associated with X-linked 
hyper-IgM syndrome, characterized by an inability to produce IgG, IgA and IgE isotypes 
(37).  
 In multiple rodent transplant models, anti-CD40L mAb treatment, which disrupts 
the CD40/CD40L pathway, has been very effective in preventing acute allograft rejection 
(38). Inductive treatment with anti-CD40L mAb can prevent rejection of heart, kidney, 
and islet allografts (reviewed in (39)). CD40L deficient mice also exhibit prolonged heart 
and islet graft acceptance. CD40L blockade in a stringent model of transplant, skin 
allografts, is not sufficient therapy itself and must be combined with additional therapies, 
including donor specific transfusion (DST), CTLA-4 IgG or anti-45RB in order to 




prolong allograft survival in rodents encouraged translation studies. Primate trials 
employing Rhesus monkeys showed promise when 5 monthly doses of anti-CD40L mAb 
permitted prolonged survival of kidney and pancreatic islet allografts (39). However, 
once the therapy was withdrawn, the monkeys rejected their grafts, indicating that anti-
CD40L mAb induced immunosuppression, rather than classical tolerance in primates. 
Even more disappointing were the results of phase 1 clinical trials, in which anti-CD40L 
mAb treatment was associated with thromboembolic events as a result of CD40L 
expression on platelets and subsequent aggregation (40). Research is currently being 
conducted to try and circumvent problems associated with anti-CD40L mAb therapy. 
CD28:CD80/CD86  
 In the early 1980‟s, a T cell membrane receptor, CD28, was identified to enhance 
TCR-induced proliferation and differentiation of naïve T cells (41). CD28 is 
constitutively expressed both on mouse and human T cells (42), and its ligands, CD80 
(B7.1) and CD86 (B7.2), are upregulated on APCs by CD40 ligation and the cytokines, 
IL-4 and IFN (41). Even in conjunction with low TCR occupancy, CD28 is potent at 
inducing a synergistic signal in naïve T cells to activate transcription factors including 
NF-κB, nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) (43-
46), which control cell cycle, survival and differentiation. Following binding of 
CD80/CD86 on APCs, CD28-mediated signals also upregulate IL-2 production (47), IL-
2R expression (48) and the secretion of IFN, granulocyte macrophage colony-
stimulating factor (GM-CSF), TNF, IL-1, IL-3 and IL-4 by T cells (41). T cell death 
signals and inhibition of cell cycle progression can be reversed by CD28 co-stimulation. 




on NF-κB activation (49, 50). In addition, the pro-apoptotic transcription factor p73 is 
inhibited in T cells following CD28 signaling, further facilitating T cell survival (51). 
 CD28 deficient mice exhibit reduced immune responses toward infections (52) 
(53), allograft antigens (54, 55), graft-versus-host-disease (GVHD) (56), contact 
hypersensitivity (57) and asthma (58). These mice exhibit impaired T cell proliferation 
and IL-2 production (41). Consistently, CD80/CD86 deficiency also results in impaired T 
cell responses (48, 59) and prolonged allograft survival in the absence of 
immunosuppressive agents (42, 60).  
 Although CD28 generates a strong co-stimulatory signal for naïve cells after TCR 
stimulation, T cell derived cytotoxic T lymphocyte associated antigen 4 (CTLA-4) 
provides a blunting signal to contain the immune response (61). CTLA-4 exhibits greater 
than one log higher affinity for CD80/CD86 than CD28 and generates an inhibitory 
signal to the T cell (61). CTLA-4 is present on naïve cells at a very low level but is 
rapidly upregulated following T cell activation and is expressed at its highest level during 
the late stages of T cell priming (62). This co-inhibitor acts through a variety of 
mechanisms. Firstly, CTLA-4 signaling actively suppresses CD28 co-stimulation (63). 
Additional mechanisms include the inhibition of cell-cycle progression (62), a direct 
inhibitory interaction with CTLA-4 and the TCR- chain (64), induction of 
immunosuppressive cytokines, such as TGFβ (65), and activation of Treg cells (66). 
Ligation of CTLA-4 has been demonstrated to induce peripheral T cell tolerance and 
anergy (67, 68). CTLA-4 deficient mice exhibit fatal lymphoproliferative disorders that 
can be eliminated with the introduction of CD28 deficiency, providing further support 




1.5 Helper T cell differentiation 
 Following engagement of the TCR with the appropriate peptide-MHC complex 
and co-stimulatory signals, clonal expansion of the responding T cell population and 
rapid differentiation into CD4+ helper T (Th) cells occurs (reviewed in (69, 70)). These 
Th cells are critical mediators in the immune response. Th cells mount a response 
contingent on the polarizing conditions that exist when the T cells first encounters 
antigen, including the type of APC that presents the antigen, the co-stimulatory pathway 
signaling employed, the cytokines present, and the concentration of antigen (71). During 
an immune response, naïve Th cells can differentiate into 4 lineages of effector T cells: 
Th1 cells secrete IFNγ and combat intracellular infections that require cell-mediated 
immunity, Th2 cells secrete IL-4 and defend against extracellular parasites, Th17 cells 
secrete IL-17 and combat extracellular bacteria, and Treg secrete a variety of suppressor 
molecules and inhibit immune responses (Figure 2) (reviewed in (72)).  
Th1 
 Naïve CD4+ T cells activated through TCR engagement and exposed to APC-
derived IFNγ and IL-12 differentiate into Th1 cells (72). This is thought to occur in two 
steps with two corresponding waves of expression of the transcription factor, T-box 
expressed in T cells (T-bet) (73). In the early polarizing phase, IFNγ produced by cells of 
the innate immune system, such as NK cells, DCs and macrophages, synergistically acts 
with TCR signaling to induce T-bet expression in addition to IFNγ (73). The critical role 





Th cells are critical mediators in the immune 
response.  Th cells mount a response contingent on the polarizing conditions that exist when the T 
cells first encounter antigen, including the type of APC that present antigen, the co-stimulatory 
pathway signaling employed, the cytokines present, and the concentration of antigen.  During an 
immune response, undifferentiated Th cells can differentiate into 4 lineages of effector T cells: 
Th1, Th2, Th17 and Treg.  Figure adapted from (74). 
 
 
mice, which do not exhibit a functional CD4+Th1 response (75). These mice demonstrate 
a significant shift in Th1 to Th2 lineage development and an increased susceptibility to 
intracellular pathogens (75). Following termination of TCR signaling, IL-12R2 
expression is upregulated and innate immune cell-derived IL-12 maintains the second 
phase of T-bet expression, stabilizing the Th1 phenotype and promoting further 
expansion of Th1 cells. The early wave of T-bet expression is induced by STAT1, while 
STAT4 is required for the second wave of T-bet expression. Upon recognition of antigen, 
effector Th1 cells will secrete abundant IFNγ, further reinforcing the differentiation of 




more Th1 cells (76). This two step process requires naïve T cells to receive pro-
inflammatory signals beyond the acute TCR signaling phase of the response before 
complete commitment to the Th1 lineage occurs.  
Th1 cells promote the activation of macrophages and mobilize the cellular arm of 
the immune response to infiltrate into sites of inflammation and combat intracellular 
pathogens (72). These cells promote delayed type hypersensitivity (DTH) and cytotoxic T 
lymphocyte (CTL) responses (described later in the chapter) (69). Th1 cells generate the 
pro-inflammatory cytokines IFNγ, TNF-, IL-2 and lymphotoxin-. Th1 generated 
cytokines activate the microbicidal activity of macrophages to efficiently destroy 
intracellular pathogens. In addition, Th1- derived IFNγ stimulates B cells to generate 
antibodies that enhance opsonization by specifically upregulating the subclasses IgG2a 
and IgG2b in the mouse and IgG1 and IgG3 in humans (77). Further, IFNγ enhances 
antigen presentation by upregulating MHC expression on cell surfaces (78). The 
importance of IFNγ in the Th1 response is underscored in mice that are deficient in the 
IFNγ receptor (79). These mice are unable to control viral and intracellular bacterial 
infections. 
Th2      
If a naïve Th cell is exposed to IL-4 following TCR engagement, signaling 
through STAT6 and activation of the transcription factor GATA3 promotes Th2 cell 
differentiation (80). GATA3 initiates chromatin remodeling of the IL-4, IL-5 and IL-13 
locus, permitting additional transcription factors involved in Th2 development to activate 
the loci (81-83). High levels of IL-4 production further induce GATA3 expression 




The source of IL-4 that initiates the development of a Th2 response was initially 
hypothesized to originate from DC signals in the form of ligands for the T cell Notch 
receptor (85). Notch signaling in T cells was believed to trigger IL-4 production by 
developing Th2 cells. Support for this was derived from experiments in Notch 1 and 2 
deficient mice, which demonstrate impaired Th2 cell differentiation. However, mounting 
evidence suggests that both mast cells and/or basophils are the original generators of IL-4 
(86). The importance of GATA3 in promoting Th2 differentiation was demonstrated 
when T cells were infected with a retroviral vector that expresses the GATA3 
transcription factor (87). The transduced cells exhibited rapid expansion into Th2 effector 
cells. GATA3 suppresses STAT4 and IL12R2 expression, thereby inhibiting Th1 
lineage development (88), while the Th1 transcription factor, T-bet, interacts with 
GATA3 and inhibits Th2 differentiation (75).       
Th2 cells secrete cytokines including IL-4, IL-13, IL-5, IL-9, and IL-10, which 
are essential for optimal antibody production and elimination of extracellular pathogens 
(69). Cytokines produced by Th2 cells drive B cells to become activated, differentiate 
and produce Th2-dependent antibody isotypes such as IgE and IgG1 (89). In addition to 
stimulating B cell proliferation and differentiation, IL-4 upregulates MHC class II 
induction. IL-4 deficient mice fail to induce Th2 cells, exhibit reduced IgG1 and IgE 
production and mount inappropriate Th1 responses when challenged with extracellular 
pathogens (89). IL-5 enhances the generation of eosinophils and basophils by the bone 
marrow, while IL-9 stimulates mast cell production and activation and further amplifies 
the Th2 response (90). Th2 responses are characterized by tissue infiltration by 




cytokines, specifically, IL-4, IL-5, IL-9 and IL-13 are strongly implicated in allergic 
reactions and airway inflammation.         
Th17 
 The Th17 lineage is a recently identified T helper subset of the immune system 
that produces the cytokine, IL-17 (reviewed in (91)). There are six IL-17 family 
members, termed IL-17A-F. CD4+ memory T cells were initially identified as the 
generators of IL-17, but CD8+ T cells,  T cells, neutrophils, eosinophils and 
monocytes, have also been demonstrated to produce this cytokine (74). A diverse array of 
tissues expresses the IL-17R and recently cardiomyocytes have been demonstrated to 
generate significant amounts of this cytokine (92). TGFβ in association with IL-6 or IL-
21 favors the commitment of CD4+ T cells to the Th17 lineage and induces RORT, 
which promotes IL-23 receptor and IL-17 gene expression (93-95). STAT3, activated by 
both IL-6 and IL-23, binds to the IL-17 promoter and activates transcription (74). IL-21, 
which is also produced by Th17, is important for amplifying the response, while IL-23 is 
critical for maintenance of the lineage and continued secretion of IL-17 (96). Cytokines 
produced by Th1 and Th2 cells inhibit Th17 lineage differentiation as do the transcription 
factors, T-bet and FoxP3 (74).  
IL-17 stimulates stromal cells, such as fibroblasts, endothelial cells, and epithelial 
cells to produce IL-6, IL-8, granulocyte colony stimulating factor (G-CSF), and 
prostaglandin E2 (PGE2) (91, 97, 98). IL-17 also up-regulates critical chemoattractants, 
such as CXCL1 and CXCL2 (91, 97, 98). These chemokines are important in 
granulopoiesis and in the recruitment of monocytes and neutrophils to sites of 




systemic hematopoiesis and inflammation in response to high expression of G-CSF and 
stem cell factor (99). Conversely, IL-17RA knockout mice demonstrate deficiencies in G-
CSF, granulopoiesis, and increased susceptibility to Klebsilla pneumoniae (100). IL-17 
deficient mice exhibit reduced delayed-type hypersensitivity, airway hypersensitivity and 
contact hypersensitivity responses, but normal host versus graft reaction (HVGR), 
indicating that donor CD4+ T cell produced IL-17 is not necessary for allo-specific CD8+ 
T cell activation (101).  
 Th17 lineage induction is strongly associated with autoimmune diseases (102-
104). Increased IL-17A transcript levels are detected in patients with inflammatory bowel 
disease (102). In rheumatoid arthritis, IL-17 mediates matrix metalloproteinase 1 
(MMP1) activity in the joint synovium and is implicated in tissue destruction (103). 
Excessive IL-17 production has also been implicated in asthma and experimental allergic 
encephalomyelitis (105). IL-17 has also recently been identified as a pro-fibrotic cytokine 
and IL-17 production is associated with both pulmonary fibrosis and scleroderma (104). 
The mechanisms by which IL-17 may mediate fibrosis will be discussed at length in 
Chapter 5. 
Regulatory T Cells 
Treg overview 
 Over a century ago, Paul Ehrlich recognized that goats could generate antibodies 
against the blood group antigens of other goats but did not generate a response against 
their own (106). Ehrlich proposed that the immune system is programmed to avoid the 
induction of autoreactive responses, and his studies became the first experimental 




separate maintenance mechanisms: recessive and dominant tolerance (reviewed in (107)). 
Recessive tolerance involves the elimination of self-reactive thymoyctes or chronically 
stimulated peripheral T cells by apoptosis or anergy. Dominant tolerance is mediated by a 
specialized subset of immune cells, most commonly by Treg, which are dedicated to 
suppressing immune responses and maintaining immune homeostasis. Treg can be 
generated in the thymus and are referred to as natural Treg (nTreg) or induced in the 
periphery (iTreg) from naïve CD4+ T cells (reviewed in (107)). iTreg include type 1 
regulatory cells T regulatory 1 (Tr1) and T helper 3 (Th3). The Tr1 cells express high 
levels of IL-10, TGFβ, and IL-5. Naïve CD4+ T cells in the presence of chronic 
inflammation, immunosuppressive drugs, and soluble proteins develop into Tr1 cells that 
secrete IL-10 and TGFβ (108). Th3 cells are induced through oral antigen administration 
and suppress through TGFβ production. All Treg, regardless of the location of 
generation, express the forkhead-winged helix transcription factor gene (FoxP3), which 
has become the most definitive marker for Treg in both mice and humans (109) in 
addition to the IL-2 receptor alpha chain, CD25 (110). Regulatory cells also reportedly 
express glucocorticoid-induced TNFR (GITR), OX40, and/or CTLA-4 on their cell 
surface (111). Both Treg subsets suppress pathogenic immune responses via a variety of 
mechanisms including: 1) through the production of anti-inflammatory cytokines; 2) 
through direct Treg-T effector or Treg-naïve T cell interactions; and 3) through 
modulating the activation state and function of APCs (112). Treg are important in 





 Sustained FoxP3 expression in mature Treg is requisite for Treg cell maintenance 
and suppressor function (113). Stable FoxP3 expression is required for Treg 
differentiation for suppressor function, proliferation, and metabolic fitness (107, 113). 
Deficiency in FoxP3 expression, as observed in humans suffering from IPEX (immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome or in the scurfy 
mouse, results in an early onset lymphoproliferative disease affecting multiple organs and 
tissues and results in death (114-118). This pathology is due to T cell acquisition of 
effector cytokine production, such as IL-2, IL-17, IL-4, IFNγ and self-targeted immune-
mediated tissue destruction (119, 120). FoxP3 is an X-linked gene in both humans and 
mice that is heavily regulated (reviewed in (107)). Several transcription factors interact 
with and activate the FoxP3 locus through conserved noncoding sequence 1 (FoxP3-
CNS1) and the conserved noncoding sequence 2 (FoxP3-CNS2). NFAT, NF-κB, AP-1, 
CREB-ATF-1 and STAT5 have all been demonstrated to bind to the FoxP3 promoter and 
upregulate its expression (121). FoxP3 expression is induced in nTreg by STAT5 in 
response to combined signaling by the TCR, the IL-2R and other gamma chain (c) 
cytokine receptors, including IL-7, and IL-15 (107, 122). STAT5 binds to the FoxP3 
locus and alters chromatin characteristics in the FoxP3-CNS2 element, directly driving 
FoxP3 transcription (123). It has been demonstrated that STAT5 plays a non-redundant 
role in promoting survival or expansion of nTreg: In the absence of STAT5, there is a 
significant reduction in FoxP3+CD4+ nTreg (123).  
Unlike nTreg, which do not require TGFβ signaling to induce FoxP3 expression 




FoxP3-CNS1 response element (125). TGFβ cooperates with TCR signaling in naïve T 
cells to induce FoxP3 partially by inactivating the cell-cycle dependent recruitment and 
maintenance of a negative regulator of FoxP3, DNA methyltransferase (DNMT1) (126). 
There are additional binding sites within the FoxP3-CNS1 element for NFAT and STAT5 
dependent regulation of FoxP3, which has been demonstrated in vitro (reviewed in 
(107)).  
Thymically-derived, nTreg 
 Insight into the existence of the thymically derived subset of Treg that are capable 
of mediating immune tolerance arose from neonatal thymectomy experiments (127). 
Thymectomy of mice between days 2-4 post-natal resulted in T cell-mediated 
autoimmunity that could be alleviated through thymus engrafting or adoptive transfer of 
thymocytes or splenocytes from genetically identical adult mice (127). These 
experiments indicated that a subset of cells generated a few days post-natal in a mouse 
thymus mediates tolerance in a dominant manner. In 1995, Sakaguchi described a 
population of CD4+ cells expressing CD25 with the ability to suppress immune 
responses in multiple experimental models (128). Further studies revealed the critical role 
of FoxP3 expression in this subset of cells for Treg differentiation (113, 119, 129), 
maintenance and suppressor function (130, 131). 
 FoxP3 induction in nTreg occurs late in differentiation when thymocytes have 
differentiated into single positive (SP) CD4+ thymocytes (107). During thymic T cell 
development, bone marrow precursor cells migrate to the thymus and interact with 
thymic stroma (reviewed in (132)). Distinct thymic microenvironments and precursor cell 




cell maturation. The first major checkpoint in T cell development occurs at the positive 
selection phase, where CD4CD8 double positive (DP) thymocytes have reached the 
cortical region of the thymus and randomly generated a TCR repertoire (132). At this 
point, the TCR of DP thymocytes interacts with self peptide-MHC complexes displayed 
by thymic cortical epithelial cells. The DP thymocytes that exhibit weak affinity 
interactions for self peptide-MHC differentiate into immature SP CD4 and CD8 
thymocytes (132). The selected SP thymocytes proceed to the thymic medullary region, 
where they undergo negative selection. Negative selection eliminates SP thymocytes that 
demonstrate high-affinity interactions with self peptide-MHC expressed primarily on 
thymic medullary epithelial cells and dendritic cells (133). Hence, negative selection 
eliminates the majority of T cells bearing TCRs with high affinity for self, and this 
process constitutes central tolerance. However, some SP CD4+ thymocytes that manifest 
very strong TCR signaling undergo selective survival. These self-reactive T cells 
upregulate FoxP3 expression and mature into nTreg (133). Further investigation revealed 
that there is a narrow range of affinity of self-reactive peptide/TCR interactions between 
negative selection and positive selection that satisfies the conditions for FoxP3 induction 
(107). The importance of FoxP3 in nTreg differentiation and suppressive capacity at this 
step is illustrated in FoxP3-/- mice. In these mice, the cells that would normally 
differentiate into nTreg would, in the absence of this key transcription factor, fail to 
mature into regulatory cells. Upon release into the periphery, the T cells become 
activated and assume effector function, resulting in autoimmune disease (reviewed in 




 In addition to TCR engagement, co-stimulatory signals (134) and cytokines play a 
pivotal cell-intrinsic role in nTreg differentiation (135). The importance of CD28 in 
nTreg differentiation was revealed in CD28 and CD80/CD86 deficient mice that show a 
significant reduction in nTreg (134). The CD28 cytoplasmic tail Ick-binding domain is 
critical for the induction of FoxP3 in nTreg. Downstream mediators of CD28 co-
stimulatory signals include NFAT, AP-1 and NF-κB, all three of which can bind and 
activate the FoxP3 promoter (reviewed in (107)). An additional signal in the form of c 
cytokines, including IL-2, IL-7 and IL-15 are also critical for nTreg differentiation. Mice 
lacking IL-2 or the IL-2R exhibit 50% less nTreg compared to WT, while mice with a 
combined deficiency of IL-2, IL-7 and IL-15 are completely devoid of nTreg (111, 112) . 
TCR engagement in nTreg precursor cells results in upregulation of CD25 and enhanced 
responsiveness to IL-2 signals (136). STAT5, activated downstream of IL-2 and the 
aforementioned c cytokines, induces FoxP3 expression through changes in chromatin 
structure at the locus, promotes survival and expansion of nTreg (112, 113). 
Peripheral iTreg 
 iTreg were first identified in mice treated with very small doses of antigen by 
osmotic pump delivery (137). The conversion of alloantigen specific CD4+ T cells into 
FoxP3+ iTreg was also observed in tolerized mice treated with non-depleting CD4+ 
mAbs (138). While the majority of Treg in the periphery are of thymic origin (107), 
FoxP3 expression and suppressive capacity can be induced in peripheral naïve 
CD4+CD25- T cells by: 1) a combination of strong TCR signal and high concentrations 
of TGFβ (126) ; 2) co-stimulation in the presence of inhibitory cytokines, such as TGFβ; 




repertoires comparing CD4+FoxP3- and CD4+FoxP3+ iTreg revealed only partial 
overlap in TCR resemblance, providing support that iTreg cell differentiation requires a 
distinct TCR specificity that promotes efficient FoxP3 induction (reviewed in (135)). In 
addition to TCR signal, CTLA-4 is required for TGFβ-mediated iTreg in vitro. However, 
CD28 and CD28 associated NF-κB signaling is dispensable for iTreg differentiation 
(135). In fact, CD28 cross-linking prevents FoxP3 induction in peripheral naïve CD4+ T 
cells upon stimulation with TGFβ (reviewed in (133)). In vitro, TGFβ-induction of Treg 
requires IL-2 (140), which not only directs STAT5-dependent regulation of the FoxP3 
promoter and promotes cell survival, but also opposes differentiation of activated CD4+ 
T cells into Th17 cells in the presence of TGFβ (100). TGFβ mediated Smad2 and NFAT 
binding to FoxP3CNS1 is critical in peripheral FoxP3 induction and, in collaboration 
with TCR signaling, induces FoxP3 through DNMT1 inactivation and chromatin 
remodeling (reviewed in (107)).  
 The generation of iTreg occurs in diverse microenvironments. iTreg have been 
observed in the lymph nodes during oral tolerance, the lamina propria of the gut in 
response to microbiota and food antigens, tumors, chronically inflamed tissue  and 
transplanted tissue (reviewed in (107, 141)). In these iTreg cell-dominated environments, 
infectious tolerance, defined as the spread of tolerance to new groups of T cells is thought 
to occur through the recruitment and induction of FoxP3-CD4+CD25- T cells into 
FoxP3+CD4+CD25+ with suppressive capacity (142). It was recently demonstrated that 
TGFβ is expressed on the cell surface of activated, but not resting Treg, and that Treg 
derived TGFβ is essential for inhibiting proliferation of activated, but not naïve T cells 




to antigen-specific naïve T cells indicating that infectious tolerance can be conferred in a 
TGFβ-dependent manner (143).  
Treg maintenance 
The three main factors critical for homeostatic maintenance of both natural and 
induced Treg in the periphery include: IL-2, TGFβ and CD28 ligation (133). IL-2 plays 
an important role in Treg proliferation and contributes to Treg function (107, 111, 144). 
The requirement for TGFβ in Treg maintenance was revealed when its absence resulted 
in decreased peripheral Treg populations despite normal thymic output (124). While 
CD28 engagement is not necessary for the generation of iTreg, this molecule is important 
for both natural and induced Treg homeostasis in the periphery (reviewed in (112)). 
These factors induce signaling pathways that mediate permissive chromatin 
modifications within the FoxP3 promoter to enhance gene expression. In the absence of 
any of these factors, the number of Treg within the periphery decrease (107).  
 A variety of molecules can reverse FoxP3 and Treg suppressor activity (107). In 
vitro cross-linking of OX40, results in a loss of FoxP3 expression and suppressor 
function in mature Treg (107). In addition, GITR ligation specifically on responders, but 
not Treg, renders the effector cells unable to respond to Treg inhibition (145). Finally, in 
mouse Treg, engagement of the toll-like receptor 2 (TLR2) on Treg has been 
demonstrated to reverse the regulatory cell‟s suppressive effect (112).       
Treg migration 
 The immune response requires efficient migration of lymphocytes throughout the 
body between lymphoid and non-lymphoid organs. This trafficking depends primarily on 




(leukotrienes and prostaglandins), defensins, the complement proteins, C3a and C5a, and 
anti-microbial peptides (146). Chemokines can be classified as inflammatory/inducible or 
homeostatic/lymphoid depending on the location of chemokine production and the type 
of stimuli elicited (146). Recognition of a chemoattractant by a lymphocyte initiates a 
process of vascular attachment, transendothelial migration, and tissue migration under 
chemotaxis (147). This process is mediated through lymphocyte cell surface adhesion and 
chemoattractant receptors (147). Cell adhesion molecules, such as integrins and selectins, 
are expressed on the tissue endothelium and are required for lymphocyte adhesion and 
transmigration. Selectins permit weak bonds to form between lymphocytes and activated 
endothelial cells, enabling the lymphocytes to roll and tether along the internal surface of 
the endothelial cell (148). Activation of the lymphocyte by chemokines induces a 
conformational change in lymphocyte integrins, which, in association with the 
appropriate cell adhesion molecules expressed on the endothelium, allows the 
lymphocyte to adhere with greater strength and transmigrate into the tissue (147). The 
extravasated lymphocyte follows chemoattractant gradients to the site of inflammation. 
 There is significant overlap between chemokine expression on CD4+CD25- T 
cells and CD4+CD25+ Treg, which is largely a function of Treg chemotaxis to sites of 
inflammation in order to control effector T cell function (149). CD25+ cells demonstrate 
elevated expression of the chemokine receptors CXCR3 (150), CCR4 and CCR8 (151) 
and migrate in response to their respective ligands, eotaxin, CCL17 and CCL1 (152). The 
importance of Treg expressed CCR4 in homing to sites of inflammation and suppressing 
effector function was illustrated in the enrichment of CCR4 expressing Treg in ovarian 




cardiac allografts and tolerance induction in recipients treated with anti-CD40L mAb 
(154).  
 Selectin expression in Treg is crucial for Treg homing and suppressive capacity in 
vivo. In a skin inflammation model, Treg from VII-deficient mice, which lack E/P 
selectin ligands, were unable to migrate into the inflamed tissue and inhibit Th1-mediated 
delayed-type hypersensitivity (155). L-selectin (CD62L) is also important in homing to 
lymph nodes and migration into tissue in which acute or chronic inflammation is 
occurring (156). CD62L+ Treg are more potent suppressors than CD62L- Treg, and 
exhibit enhanced survival (157). In vivo, CD62L+ Treg demonstrate superior suppressive 
abilities in a mouse model of autoimmune diabetes (158). In addition, expansion of 
CD62L+ Treg preferentially migrate to the lymph node of tolerant allograft recipients and 
show alloantigen-specific suppressor function (159). Clearly, Treg migration is important 
for Treg function and peripheral tolerance induction.   
Treg suppression 
 Treg are potent suppressors of T cell proliferation and effector function both in 
vitro and in vivo (reviewed in (112)). The cellular targets of FoxP3+Treg suppression 
include CD4+ and CD8+ T cells, DCs, B cells, macrophages, osteoblasts, mast cells, NK 
cells and NKT cells (112). There are multiple mechanisms by which Treg can directly 
and indirectly suppress CD4+CD25- T cells. Treg impact almost every feature of effector 
T cell function, including T cell activation, IL-2 production, proliferation, and trafficking 
(147). There are multiple mechanisms by which Treg can directly and indirectly suppress 
CD4+CD25- T cells. Treg can directly suppress CD4+CD25- T cells via IL-2 




cytolysis of target cells and cell surface molecule production that initiates cell cycle arrest 
(galectin-1) (112). Treg can indirectly inhibit CD4+CD25- T cells by suppressing the 
function and activation of APCs through CD80/CD86 down-regulation, binding of the 
lymphocyte activation gene-3 (LAG-3) to the MHC class II molecules on DCs thereby 
suppressing maturation, inactivation of pro-inflammatory extracellular ATP by CD39, 
and competing against CD4+CD25- T cells for DC interactions employing the Treg 
receptor, neuropilin (Nrp-1) (112). 
 IL-2 
 Both in vivo and in vitro studies have demonstrated that Treg cell-mediated 
inhibition of IL-2 can suppress both proliferation and cytokine production in 
CD4+CD25- T cells (160-162). Treg may inhibit IL-2 by directly competing with 
CD4+CD25- T cells for IL-2 consumption, resulting in diminished proliferation of the 
responder cells followed by BIM-mediated apoptosis (163). Studies also reveal that Treg 
can suppress IL-2 production in CD4+CD25- T cells by inhibiting the induction of IL-2 
gene expression (160-162). IL-2 also enhances Treg suppressive function. At high levels 
of IL-2, Treg will become activated and expand (144). IL-2 also primes Treg to produce 
IL-10 upon restimulation, either upon migration into the secondary lymphoid organs or 
within inflamed tissue (144). Therefore, Treg uptake of IL-2 not only suppresses T cell 
activation but expands the Treg population and upregulates production of a suppressor 
cytokine, IL-10, to control T cells that may have escaped suppression initially and have 




1.6 TGF gene expression, signaling and suppressor function 
 TGF is a multifunctional cytokine that controls proliferation, differentiation, and 
other functions in diverse cell types (164). TGF belongs to a superfamily of proteins 
that include morphogenic proteins, activins, and growth differentiation factors (165). 
Mammals express three homologous isoforms of TGFβ, each of which is encoded by a 
different gene. TGFβ1 is the predominant isoform expressed in the immune system. 
TGFβ2 and 3 play important roles in development and are primarily expressed in 
mesenchymal tissues and bones (reviewed in (164)). TGFβ is synthesized as a prepro-
TGFβ precursor (166). This precursor contains a signal peptide that is removed when the 
TGFβ precursor is processed in the Golgi (166). TGFβ is noncovalently associated with a 
latency-associated protein (LAP) forming the small latent TGFβ complex (SLC) (167). 
The SLC can be secreted or it can further associate with the latent TGFβ binding protein, 
forming a large complex (LLC). The SLC and LLC sequester TGFβ to the extracellular 
matrix, preventing the cytokine from interacting with its receptor (167). Activation of 
TGFβ requires liberation from the complexes through proteolytic cleavage or a 
conformational change (167).  
TGFβ becomes activated following dissociation from LAP or LTBP and mediates 
signaling by binding TGFβ type I and II transmembrane serine/threonine kinase receptors 
(166). Following TGFβ receptor ligation, activin receptor like kinase (ALK5) 
phosphorylates Smad2 and Smad3, which translocate to the nucleus in complex with 
Smad4 (reviewed in (168)). In association with other transcription factors, the Smad 
complex binds target promoters of a multitude of genes and regulates expression. TGFβ 




signaling is down-regulated by the expression of Smad7, which competes with Smad2 
and Smad3 binding and degrades these factors through ubiquitin ligase complexes (168). 
Unlike isoforms 2 and 3 gene expression, which are regulated primarily by 
developmental or hormonal signals, little is known about the transcriptional regulation of 
TGFβ1. The promoter of TGFβ1 contains binding sites for AP-1 where c-jun and c-fos 
induced by TGFβ signaling bind to and stimulate additional TGFβ1 production (164). 
However, AP-1 may have a dual role in regulating TGFβ1, depending on the context and 
the cell type, because it has been demonstrated that the AP-1 activators, c-Jun-NH2-
terminal kinase 1 and 2 (JNK1, JNK2), inhibit TGFβ1 expression in fibroblasts (164). 
TGFβ1 gene expression may not correlate with secreted protein expression suggesting 
that TGFβ1 is post-transcriptionally regulated. Indeed, the TGFβ1 transcript found in 
abundance has a long 5‟ untranslated region that is associated with negative regulation of 
TGFβ translation (164). The exact mechanism is unknown.   
TGFβ regulates cell proliferation 
 Mice with a systemic TGFβ deficiency (TGFβ-/- mice) (169) and mice that 
possess a T cell specific cell specific abrogation of TGFβ signaling (CD4-DNR mice) 
(170) manifest multi-focal autoimmune diseases, characterized by spontaneous T cell 
activation, hyperproliferation, effector cell induction and significant inflammatory 
cytokine production. TGFβ critically regulates Th and CTL differentiation, in addition to 
T and B cell proliferation, activation and survival (reviewed in (164)). TGFβ suppresses 
T cell proliferation by inhibiting IL-2 transcription (171) and by affecting cell cycle 
progression through selective upregulation of cyclin-dependent kinase inhibitors (p15, 




cyclin E (164). However, TGFβ-mediated inhibition of cell proliferation depends on the 
activation status of the responder. CD28 co-stimulation over-rides TGFβ suppression in 
TCR-mediated naïve T cell proliferation (172). In addition, while TGFβ inhibits naïve T 
and B cells, it has minimal effects on activated cells as a consequence of reduced 
TGFβRII expression (141). The cytokine, IL-10, can ameliorate this by enhancing 
TGFβRII expression and conferring TGFβ responsiveness in activated T cells (141). 
Preferential TGFβ inhibition of naïve cells in the absence of co-stimulation is thought to 
dampen T cell responses toward self-antigen, while the limited ability of TGFβ to 
suppress TCR-activated cells that receive strong co-stimulatory signals, permits the 
development of cellular immunity toward infections (173). 
TGFβ regulates differentiation of Th1 and Th2 cells 
 TGFβ is capable of opposing both Th1 and Th2 cell differentiation (Figure 3). 
Under polarizing conditions, activated naïve CD4+ T cells differentiate into helper T 
cells (69). TGFβ effectively blocks Th1 differentiation through the reduction of IL-
12Rβ2 and T-bet gene expression (174, 175). TGFβ may achieve this by directly 
regulating IFNγ or T-bet transcription or by down-regulating STAT4 expression, which is 
a transcription factor activated by IL-12 that upregulates  IFNγ expression upon T cell 
priming (174, 175). Gorelik and colleagues demonstrate that TGFβ directly inhibits 
GATA3 expression, thereby preventing Th2 differentiation (176). In addition, TGFβ 
interferes with TCR and co-stimulatory signaling by suppressing the activation of the Tec 
kinase, Ick, and by inhibiting calcium influx following TCR/CD28 stimulation (177). 
Impairments in calcium signaling negatively impacts NFAT, which is a transcription 







The pathways that are used by the host immune 
system to reject an organ evolved to combat intracellular and extracellular pathogens and TGFβ 
can play either an anti-inflammatory or pro-inflammatory role. TGFβ alone can drive an 
undifferentiated T helper cell to become a T regulatory cell, which is a T cell subset that actively 
suppresses immune responses and maintains immunological tolerance. TGFβ has been shown to 
inhibit differentiation of Th1 cells, which express IFNγ and mobilize the cellular arm of the 
immune system to combat intracellular pathogens. TGFβ also suppresses Th2 cells that secrete 
IL-4 and are essential for elimination of parasitic worms. TGFβ in conjunction with IL-6 or IL-21 




TGFβ inhibits CD8+ T cell differentiation  
 
 The suppressive effect of TGFβ on CD8+ T cells was revealed in experiments in 
which CD8+ T cells activated in the presence of TGFβ do not acquire cytotoxic T 
lymphocyte functions and weakly proliferate (reviewed in (164)). This is due to the 
inhibition of multiple effector molecules in CD8+ T cells (178). TGFβ suppresses 
perforin, T-bet and IFNγ gene expression in these cells. In addition, TGFβ affects the 
death receptor cytotoxic pathway of CD8+ T cells by inhibiting the expression of Fas 
ligand (164). However, similar to CD4+ inhibition by TGFβ, CD8+ T cell inhibition is 




context dependent and co-stimulatory and cytokine signaling pathways can over-ride the 
suppressive effect of TGFβ (178).  
TGFβ regulation of B cells  
 TGFβ is an essential regulator of B cells as evidenced by the autoimmunity 
phenotype observed in mice with B cell-specific blockade of TGFβ signaling (179). 
Similar to its effect on T cell proliferation, TGFβ inhibits proliferation in B cells by 
repressing cyclin A expression, inactivating cdk2 and down-regulating c-myc (180). 
These alterations in cell cycle progression result in blockade at G1/S (164). TGFβ also 
inhibits B cell differentiation by preventing both light chain expression and the secreted 
form of the heavy chain (181, 182) and blocks class switching to most IgG isotypes. 
TGFβ negatively regulates B cell survival signals. TGFβ impairs IL-4 mediated STAT-6 
activation, which is an important mitogenic survival factor for B cells (164). In addition, 
TGFβ upregulates pro-apoptotic members of the BCL-2 family and induces apoptosis in 
immature and resting B cells (183).   
A negative regulator of TGFβ: Decorin 
 Decorin, an extracellular matrix protein, has received attention in cancer research 
and in fibroproliferative diseases for its ability to inhibit TGFβ (184). Decorin is a 
member of the small leucine rich proteoglycan (SLRP) family (185). The core protein of 
decorin contains 10 leucine rich repeats that interact with a number of extracellular 
proteins, including collagen, fibronectin, thrombospondin, complement component C1q, 
EGFR and TGFβ (186-188). The role of decorin in stabilizing the extracellular matrix 
(ECM) was revealed in decorin deficient mice, which exhibit abnormally fragile skin 




Decorin also negatively impacts cell proliferation, an effect mediated through the 
induction of p21(184). Decorin has been demonstrated to down-modulate TGFβ 
bioactivity both in vitro and in vivo (190-193). Decorin binds all 3 isoforms of TGFβ, 
effectively inhibiting the cytokine‟s interaction with its receptor (Figure 4). In addition, 
decorin inhibits TGFβ gene expression by interrupting TGFβ/Smad-dependent 
transcriptional events (194, 195). Decorin gene transfer has attenuated TGFβ dependent 
fibrosis in models of glomerulonephritis (196), cardiac ventricular fibrosis (197), and 
pulmonary fibrosis (198). 
Decorin is an extracellular protein and a member of the 
small leucine-rich proteoglycan family. This ECM protein binds all 3 isoforms of TGFβ, thereby 
inhibiting TGFβ‟s interaction with its receptor. In addition to inhibiting the TGFβ bioactivity, 
decorin can also negatively regulate TGFβ gene expression (199). 




1.7 Inflammatory response to allografts 
 The immune system evolved to defend against microbial pathogens, not 
transplanted organs. However, because organs are rarely transplanted between genetically 
identical individuals, the immune system recognizes the organ as “non-self“ and mounts 
a response (11). This section reviews the pathology associated with acute rejection, 
delayed type hypersensitivity, humoral rejection, hyperacute rejection, and chronic 
rejection. 
Acute allograft rejection 
 Acute cardiac rejection is characterized by a severe and localized inflammatory 
response within the allograft that results in destruction of graft tissue and loss of function 
(12). Initially, an alloantigen-independent inflammatory response occurs within hours 
post-transplantation (200, 201). This response is characterized by the activation of graft 
vascular endothelial cells and leukocyte infiltration (202). Vascular endothelial cells 
express adhesion molecules, such as ICAM-1, increasing accessibility to the graft by 
macrophages, neutrophils and dendritic cells (203). Macrophages infiltrate into the 
perivascular interstitium and express the cytokines, IL-1, IL-6, TNF and TGFβ (204). 
These cytokines serve to stimulate the migration of additional immune cells into the graft 
and, subsequently, into the recipient‟s draining lymph nodes for further immune 
activation (202).  
This initial inflammatory response occurs regardless of whether the transplant is 
an isograft or allograft and is a function of ischemic injury and tissue hypoxia that is 
incurred during organ procurement and the operative period (205). Cold ischemic time 




inflammation (205). If the organ is recovered from a donor who has sustained brain 
death, hormonal dysfunction, proinflammatory cytokine release and hemodynamic 
instability contributes to graft damage prior to transplantation (206). During surgery, 
warm ischemia injury and delayed graft function serve to amplify inflammatory 
responses that occur post-operatively (207). These initial insults to the transplant result in 
graft injury and facilitate inflammatory cell recruitment into the allograft. In accepted 
cardiac allografts, these inflammatory events can take up to 20 days to resolve (200). 
    The initial inflammatory response toward a cardiac allograft evolves 
significantly within three days post-transplant (200). At this time, the alloantigen-
dependent phase is initiated. T cells become the dominant infiltrating cells within the 
interstitium and eventually migrate throughout the graft in response to chemokines such 
as VCAM-1, MCP-1 and RANTES (207, 208). Host T cells are first activated by foreign 
or self-MHC in addition to simultaneous stimulatory signals from APCs (28). The 
activated T cells undergo clonal expansion and assume effector function. Once activated, 
recipient CD4+ T cells produce a variety of cytokines, including IL-2, IFNγ and IL-4 
(12). IL-2 drives alloreactive CD8+ T cell differentiation into cytotoxic T lymphocytes 
(CTLs), which are capable of lysing allograft cells (209). CTLs kill through the release of 
perforin/granzyme and/or ligation of Fas with FasL, which signals the allogeneic cells to 
undergo apoptosis through a caspase mediated mechanism (12). The important role CTLs 
play in rejection was demonstrated in human transplant when donor-specific CTLs were 
eluted from rejecting kidney transplants (210), and in experiments in mice when CD8+ 
effector cells were adoptively transferred and mediated rejection of skin grafts in 




mounting a Th2-dominant response characterized by an aggressive eosinophil infiltration 
(14).  CD4 helper T cells also facilitate donor-reactive Ab production in the spleen and 
lymph nodes through the activation of alloreactive B cells (described later in this chapter) 
(12). Circulating alloreactive IgG Ab are detected within 7 to 14 days post-transplant 
(200). Additional cytokines increase vascular permeability and enhance the accumulation 
of neutrophils and mononuclear cells into the graft. Histologically, acute cardiac rejection 
is associated with high numbers of infiltrating inflammatory cells, extracellular edema, 
cardiomyocyte lysis, hemorrhage and vascular damage (212). Acute rejection occurs 
rapidly in the absence of immunosuppression and results in graft failure within a matter 
of weeks post-transplantation.      
Delayed type hypersensitivity 
 Another mechanism of graft rejection is delayed type hypersensitivity (DTH) 
(12). During DTH, alloreactive CD4+ and CD8+ Th1 cells are the main mediators of 
graft rejection. Alloreactive T cells differentiate into Th1 cells that produce the pro-
inflammatory cytokines, IFNand TNF (12). IFN induces the expression of chemokines 
such as CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 to enhance the inflammatory 
response by facilitating the infiltration and activation of monocytes and macrophages 
(20). TNF and TNF serve to enhance vascular permeability and mediate local tissue 
destruction. These cytokines activate monocytes and macrophages, which infiltrate the 
grafts and secrete cytokines and chemokines to attract additional inflammatory cell 
infiltration. Macrophages shape the local inflammatory response within the graft by 
producing proteolytic enzymes, nitric oxide and additional pro-inflammatory cytokines 




of the allograft through their effects on vascular integrity and tissue injury. DTH 
responses within an allograft are characterized by edema and intense cellular infiltrate 
(12). A DTH response is sufficient to mediate allograft rejection as demonstrated by 
CD4+ T cell adoptive transfer into SCID recipients of MHC Class I- or II-disparate skin 
grafts and subsequent graft rejection (213). 
Humoral rejection 
 Advances in transvenous endomyocardial biopsies and histologic grading systems 
enhanced the diagnosis of cardiac rejection (214). However, some patients were 
diagnosed with „biopsy negative‟ heart transplant rejection (215). Many of these patients 
were experiencing humoral graft rejection (215). Hammond first described humoral 
rejection as endothelial cell swelling and vasculitis associated with deposition of IgG and 
complement as observed by fluorescent microscopy of immunostained grafts (216). 
Antibody mediated rejection (AMR) occurs when Ab engages with graft antigen resulting 
in the fixation of complement and triggering of the complement cascade (77). The 
deposition of complement was first described in kidney biopsy specimens (217). 
Complement component C4d deposition within the peritubular capillaries of these 
biopsies correlated with severe rejection and graft loss (217).  
In addition to complement-mediated cell lysis, Ab deposition and activation of 
complement in cardiac transplants is associated with both the accumulation and 
activation of leukocytes within the capillaries and arteries of the graft (77). The FcR on 
neutrophils and macrophages interacts with the Ab Fc tail and results in cellular 
activation. This interaction induces the production of various cytokines such as MCP-1, 




at the site of inflammation (12). Activation of the complement components, C3, and C5 
also results in the formation of the split products, C3a and C5a, which are small diffusible 
fragments that mediate chemotaxis and activation through C3a and C5a receptors on 
leukocytes (218). Macrophages possess complement split product receptors for C5a, the 
stimulation of which induce the production of the pro-inflammatory cytokines, IL-1, IL-
6, IL-8 and TNF- that further amplify the immune response (12). Complement 
activation of antibodies also serves as a strong positive feedback loop for B cell 
activation, maturation and Ab production because the complement split product, C3d, is 
an activating ligand for CR2 on B cells (219).  
Hyperacute allograft rejection 
 In humans, pre-formed anti-HLA antibodies occur in some patients as a result of 
previous transplant, pregnancy or transfusion (220). Major and minor blood group 
antigens can also elicit Ab responses in transplant recipients. Blood group antigens are 
expressed on endothelial cells within cardiac allografts and Abs can cross-react with 
these cells (220). Preformed alloantibodies to blood group antigens can result in a rapid—
a matter of minutes—rejection of the graft mediated by a complement-dependent reaction 
referred to as hyperacute allograft rejection (HAR) (12). Activation of the complement 
and blood clotting cascades causes vascular blockage in a cardiac allograft resulting in 
hemorrhage, thrombosis, severe injury and graft death. HAR can be avoided by 
performing cross-matching to determine whether the recipient is sensitized (has 
antibodies) to donor antigen (12). HAR is a major barrier to xenotransplantation—the 
transplantation of organs between closely related species—as a result of pre-formed anti-




antibodies are predominantly directed against Gal1,3Gal1, 4GlcNAc carbohydrate 
residues, which are expressed on endothelial cells of non-primate mammals and New 
World monkeys, but absent in humans, apes and Old World monkeys (222). As a result, 
anti-Gal antibodies are generated early in life through the encounter of Gal-expressing 
microorganisms in the intestinal tract and can compose up to 1% of antibodies in 
circulation (222).  
Chronic rejection 
 While short-term survival rates of solid organ transplants continue to improve, 
long-term graft survival remains constant (5). In vascularized organ allografts, the 
primary cause for late graft failure is CR (reviewed in (223)). CR is characterized by 
proliferation of fibroblasts within the graft, which promotes interstitial fibrosis as well as 
thickening and narrowing of the coronary vessels, a process referred to as transplant 
associated vasculopathy (TAV) (224). CR may develop in response to multiple 
mechanisms and evolve from a cell and Ab-mediated phase that leads to allograft tissue 
damage to a tissue-remodeling phase driven by cytokines and growth factors (223).  
TAV 
Over 45% of cardiac transplants exhibit TAV (5) and this pathology is a key 
feature of CR (224). Mounting evidence indicates that TAV is the result of chronic 
inflammatory responses toward vessel walls, which is strongly associated with the 
accumulation of inflammatory cells, primarily macrophages and T cells (224). TAV does 
not develop in syngeneic transplants, providing evidence that this pathology is an 
immune mediated disease (225). In experimental models of TAV, T cells migrate into the 




These alloreactive T cells also secrete cytokines that induce the expression of endothelial 
cell adhesion molecules and chemokines, such as RANTES, which attract monocytes and 
macrophages. Macrophages, in particular, are implicated in the early phases of clinical 
and experimental TAV because these cells migrate into the perivascular areas and 
produce a number of cytokines, such as IL-6 and MCP-1 in addition to a variety of 
fibrogenic and matrix proteins (226). Cytokines and chemokines secreted by 
inflammatory cells results in smooth muscle cell (SMC) activation and migration from 
the media to the intima of the graft (224). SMCs proliferate and release additional 
cytokines and extracellular matrix proteins that lead to luminal narrowing and vascular 
dysfunction (224). 
The development of alloantibodies and complement deposition also contributes to 
TAV (226). Evidence that Abs are necessary for the induction of CR stems from 
experiments in which B-cell-deficient mice employed as transplant recipients fail to 
develop the typical arterial lesions observed in TAV (227). In addition, cardiac 
transplants performed between mouse strains that produce Abs to donor antigen results in 
more severe TAV than transplants in the reverse combination, in which Abs were not 
detected (227). While Ab activation and complement deposition on vascular endothelial 
cells can result in cell lysis, sublytic amounts of complement can activate endothelial 
cells (ECs). Activated ECs release pro-fibrotic and inflammatory factors such as von 
Willebrand factor, P-selectin, IL-8, MCP-1, fibroblast growth factor (FGF), TGF, and 
platelet-derived growth factor (PDGF) (226). Immunohistochemistry staining of vascular 
endothelial cells in experimental models of TAV have revealed high expression of PDGF 




(226). In addition to the pro-fibrotic factors, the secreted inflammatory mediators 
enhance innate and adaptive immune responses within the graft (226). Complement 
activation of platelets deposited on arterial endothelial cells induce the production of 
soluble CD40L, which is the ligand for CD40 on B cells, macrophages, and DCs leading 
to amplification of the immunity toward an allograft (226). Platelets also secrete growth 
factors that promote the proliferation of endothelial cells, smooth muscle cells and 
fibroblasts.  
Interstitial fibrosis 
 Unlike the cardiomyocyte necrosis and cell death observed in acute rejection, CR 
is associated with progressive interstitial fibroproliferation and tissue remodeling (228). 
There is compelling evidence that this process is driven by alloantigen responses and may 
be the result of “smoldering, subacute rejection accumulating progressive subclinical 
damage” (228). CR is theorized to be the result of a chronic wound healing process. 
During tissue repair, fibroblasts proliferate and differentiate into myofibroblasts, which 
migrate into the wound bed. This cell type has the capacity to generate significant 
amounts of collagen and extracellular matrix proteins required to restore the tissue 
architecture (229). In normal repair, myofibroblasts appear transiently, perform their 
function in connective tissue restoration, and disappear, most likely due to apoptosis 
(229). It is the persistence of myofibroblasts within lesions that is responsible for the 
excessive collagen accumulation that leads to aberrant tissue remodeling and, in the case 
of CR, to organ failure.  
 Myofibroblast persistence within the interstitium of grafts has been observed in 




allografts, myofibroblasts are associated with progressive interstitial fibrosis (229). 
Clinical CR cardiac allografts also exhibit myofibroblasts within the intima of vessels and 
the interstitial spaces (230). The abundance of myofibroblasts strongly correlates with 
collagen deposition, progressive fibrosis and graft dysfunction (220).  
Role of TGF in CR 
 Multiple growth factors have been implicated in the activation and differentiation 
of fibroblasts into myofibroblasts, but TGF has been recognized as a pivotal cytokine in 
fibrotic diseases (231), including CR (232, 233). TGF has been implicated in fibrosis 
associated with rheumatoid arthritis, diabetic nephropathy, intestinal inflammation, and 
myocarditis (231). Further, a plethora of clinical and experimental evidence directly links 
TGF to cardiac fibrosis including: 1) collagen and ECM production in fibroblasts 
isolated from cardiac tissue is directly induced by TGF (234); 2) upregulation of TGF 
transcript and protein levels are associated with cardiac infarct scars, correlating with 
increased collagen deposition and elevated Smad 2, 3, and 4 expression (234); 3) in 
patients with cardiac fibrosis, TGF1 and LTBP levels are increased (233); 4) intragraft 
TGF transcript levels are only detected in CR cardiac allografts from recipients treated 
with anti-CD4 mAb but not in recipients treated with anti-CD40L mAb, that do not 
exhibit CR (232); and 5) gene transfer of TGF into cardiac allografts is capable of 
inducing CR (235). 
 TGF regulates fibroblast proliferation and differentiation into myofibroblasts 
and subsequent collagen synthesis (236, 237). However, additional factors must 
collaborate to promote the persistent fibrotic responses in vivo (236). In experimental 




TGF do not develop CR (232). Evidence points to connective tissue growth factor 
(CTGF) as the pivotal down-stream mediator of TGF-induced fibrosis of cardiac grafts 
in the presence of alloantigen stimulation (232). For fibroblasts to proliferate in response 
to TGF and CTGF, additional mitogenic factors, such as EGF and PDGF must also be 
present (236). In allogeneic transplants, activated endothelial cells and macrophages 
release PDGF and are most likely the cells responsible for providing fibroblasts this 
necessary mitogenic stimulus. For fibroblasts to subsequently differentiate into 
myofibroblasts, CTGF works in concert with insulin growth factor-2 (IGF-2), which is a 
growth factor expressed by cardiomyocytes (236). In this manner, TGF has the ability to 
induce cardiac fibroblast proliferation and differentiation into myofibroblasts through a 
CTGF-dependent pathway (233). However, sufficient co-mitogens must be present to 
amplify the fibrotic effect, and in CR grafts, alloantigen appears to play a key role in this 
process.   
1.8 Transplant tolerance 
 For more than half a century, the question remains as to whether elements of self-
tolerance can be exploited to achieve allograft tolerance in the absence of continued 
immunosuppression. Medawar and his colleagues demonstrated transplantation tolerance 
induced by adoptively transferring allogeneic bone marrow (BM) into neonatal mice 
(reviewed in (238)). Tolerance induction was achieved in these mice through the 
establishment of a state of mixed (recipient and donor) blood chimerism and subsequent 
purging of alloreactive cells (238). This was the first demonstration of acquired 
immunological tolerance, which exploits the recipient‟s natural tolerance mechanisms 




Tolerance in the transplant setting is defined as the indefinite acceptance of an 
allograft after a brief course of immunomodulatory treatment (238). Tolerance toward an 
allograft occurs in two phases: induction and maintenance. Induction of tolerance is 
established at the time of transplant primarily through immunosuppression. A minority of 
grafts are lost to acute rejection during the first year post-transplantation indicating that 
tolerance induction is achievable or that immunsuppression is successful (239). However, 
reprogramming the immune system to accept the allograft long-term and maintain 
tolerance in the absence of immunosuppression has proved to be a major challenge.     
Transplant tolerance is composed of central and peripheral tolerance (reviewed in 
(240)). Deletion of the majority of thymocytes that exhibit high avidity for thymically 
expressed antigen constitutes central tolerance (107). Peripheral tolerance prevents 
alloreactive responses toward the graft through the extrathymic deletion of alloreactive 
cells by apoptosis, induction of anergy, and active suppression by Treg (240). There is 
most likely overlap between the two mechanisms in tolerance induction.  
Central tolerance 
 Central tolerance in the transplant setting is primarily a function of thymocyte 
deletion analogous to self-tolerance (241). This mechanism involves the induction of 
programmed cell death (apoptosis) in thymocytes that react strongly to both self and 
donor antigen and subsequent removal of these cells from the T cell repertoire. Mixed 
hematopoietic chimerism and donor thymic transplantation are two strategies employed 
to induce central tolerance (reviewed in (242)). Mixed hematopoietic chimerism involves 
the transfusion of hematopoietic stem cells that engraft, co-exist with recipient stem cells, 




the thymus and mediate negative selection (242). As a result, the T cell repertoire is 
tolerant toward the graft (243). Donor-specific tolerance toward cardiac allografts was 
achieved in BM chimeric rats (244). In the minor MHC antigen-disparate rat model of 
CR, no TAV was observed in F-344 rats that received cardiac allografts from Lewis rats 
and donor BM, while non-chimeric control rats exhibited significant TAV (245). Donor-
specific tolerance to small bowel allograft can also be induced in this same model using 
BM chimerisms (244). Additional studies identified bone marrow cells, and not 
peripheral blood mononuclear cells (PBMCs) as the cell type critical for tolerance 
induction.  
DST of spleen or bone marrow cells prior to transplant and followed by a drug 
therapy (cyclophosphamide or busulfan) that is toxic to proliferating cells, represents a 
twist on BM chimerism but also involves specific deletion of donor-reactive cells (246). 
Using this regimen, alloreactive recipient cells that respond to donor antigen would 
selectively undergo apoptosis. DST in conjunction with cyclophosphamide has been 
demonstrated to induce both long-term cardiac (247) and skin graft acceptance (248). In 
addition, DST in concert with co-stimulation blockade, such as CD40 or ICOS-B7h 
blockade, has been shown to prolong cardiac allograft survival (249).  
Donor thymic transplantation has been less successful than mixed chimerism in 
inducing central tolerance toward a graft (242). Co-transplant of non-vascularized thymic 
tissue at the time of transplant often results in rejection of the thymus prior to the 
establishment of tolerance. To address this issue, revascularization of thymic tissue has 
been achieved using composite organs termed “thymokidneys” (250) and 




thymic tissue at the time of organ transplant. Class I MHC mismatched “thymokidneys” 
transplanted into swine treated with cyclosporine results in donor-reactive cellular and 
humoral hyporesponsiveness (252). Thymohearts transplanted across the same MHC 
barrier, however, induces alloreactivity and evidence of TAV (253). Improved techniques 
of vascularizing thymic tissue to cardiac transplants may improve this outcome.      
Peripheral tolerance 
 Mechanisms of peripheral tolerance include extrathymic cell deletion by 
apoptosis, anergy and regulatory cell suppressor activity.   All three mechanisms will be 
discussed below. 
Treg in transplant 
 There is considerable evidence in both human or experimental transplant 
recipients, that Treg are requisite for tolerance rendered spontaneously or through 
immunomodulatory therapy (171, 254-256). Treg suppression of alloreactive cells has 
been observed both in vitro and in vivo. In vitro, Treg isolated from tolerized transplant 
recipients suppress alloreactive T cell activation and proliferation in MLR (257, 258). In 
vivo, pretransplant depletion of Treg by anti-CD25 mAb, results in CR in mouse models 
that normally exhibit spontaneous tolerance, and acute rejection in models that otherwise 
manifest CR (259-261).  
The requirement for Treg as the main mediators in graft tolerance has been 
observed in a variety of tolerizing treatments and this tolerance is transferable to naïve T 
cells adoptively transferred into hosts in a process termed infectious tolerance (reviewed 
in (262)). There is considerable evidence that iTreg play a key role in infectious 




adoptively transferred into cardiac allograft transplant recipients can suppress 
alloreactivity and promote long-term graft survival (262). In addition, allograft 
acceptance in this model correlates with intragraft Treg migration. A similar correlation 
between favorable allograft outcome and a robust intragraft Treg population is frequently 
observed in human transplant (263-266), indicating the importance of Treg locally 
inhibiting alloreactive responses at the site of inflammation.  
 The development of Treg occurs through multiple mechanisms and most likely 
involves both natural and induced Treg. In vitro studies suggest that nTreg suppression 
may be allo-antigen specific or nonspecific (262), and that both the direct and indirect 
pathway of allorecognition can activate these Treg (263, 267). Likewise, induction of 
both CD4+ and CD8+ Treg in the presence of TGFβ and alloantigen ex vivo and 
subsequent transfer of these iTreg into recipients of cardiac allograft recipients, results in 
donor-reactive specific suppression and infectious tolerance (268). It was also recently 
demonstrated that TGFβ is expressed on the cell surface of activated, but not resting 
Treg, and that Treg derived TGFβ is essential for inhibiting proliferation of activated, but 
not naïve T cells (143). Further, Treg are capable of inducing FoxP3 expression and 
suppressor function to antigen-specific naïve T cells indicating that infectious tolerance 
can be conferred in a TGFβ-dependent manner (143). Most likely, a combination of 
nTreg and iTreg synergize to suppress alloreactivity and induce transplant tolerance.  
 Treg can suppress alloreactive cells through both contact dependent (66, 173) and 
independent pathways (143, 172). Contact independent-mediated suppression involves 
the secretion of the anti-inflammatory cytokines, IL-10 and TGFβ (143, 172). Contact 




with TCR engagement (66), granzyme B-mediated apoptosis (269) and cell surface 
bound TGFβ. Treg can inhibit both alloreactive Th1 and Th2 responses, prevent CTL 
development, suppress B cell proliferation, induce apoptosis, modify the function of 
APCs, convert naïve CD4+ T cells into Treg, and induce infectious tolerance (reviewed 
in (270)). While Tregs are primarily suppressive in function, in response to DC derived 
IL-6 and alloantigen, Treg can promote the development of Th17 cells (271). Therefore, 
in the transplant setting, Treg can suppress or activate alloreactive cells depending on the 
context.  
Donor-reactive cell anergy and deletion  
 Both anergy and donor-reactive cell deletion by apoptosis are thought to work in 
concert to induce tolerance (272). Anergy is defined as a state in which donor-specific T 
cells are present within the periphery, but functionally inert, failing to proliferate both in 
vitro (273) and in vivo (274). As discussed previously, in order to become fully activated, 
T cells require two signals: 1) engagement of the TCR with peptide-MHC complex and 
2) co-stimulation through the engagement of one or more T cell surface receptors with 
the corresponding molecules on APCs (ie. CD28:CD80/CD86 or CD40L:CD40) (249). 
TCR engagement with peptide-MHC with no additional co-stimulatory signal results in T 
cell anergy (275). Co-stimulatory blockade through anti-CD40L mAb, anti-CD28 mAb 
and CTLA-4-IgG treatment of transplant recipients results in prolonged allograft survival 
and tolerance induction (249, 276, 277). Evidence for anergy in bone marrow 
transplantation arises from primary MLR experiments that demonstrate allo-antigen 




 Donor-reactive T cells can undergo deletion or apoptosis by two mechanisms: 
activation induced cell death (AICD) or passive cell death (272, 279). AICD, which 
requires the presence of IL-2 and is mediated by FAS-FASL interactions, is important for 
the elimination of activated cells after repeated antigen stimulation (272, 279). The role 
for AICD in the induction of tolerance following co-stimulatory blockade was revealed in 
IL-2-/- mice and Bcl-xL mice (transgenic mice that express high levels of the anti-
apoptotic gene, Bcl-xL), whose T cells are unable to undergo AICD and are resistant to 
induction of transplantation tolerance (272, 279). Passive cell death entails the 
elimination of activated cells due to cytokine or growth factor withdrawal (280). Both 
passive apoptosis and AICD are required for induction of peripheral transplantation 
tolerance in transplant models that employ co-stimulatory blockade (CTLA-4Ig or anti-
CD40L mAb) or immunosuppression (rapamycin) (272). Additionally, in the absence of 
immunosuppression, significant levels of T cell apoptosis of graft infiltrating cells (GIC) 
into liver transplants has been shown to correlate with prolonged allograft survival (281). 
It is hypothesized that alloreactive cell death during the inductive phase of transplant is 
requisite to reduce the population of graft reactive cells to a level more conducive for 
control by anergy or regulation during the maintenance phase (272).   
T cell depletion: anti-CD4 mAb treatment 
   A variety of immunomodulatory methods have been employed in transplantation 
to promote transplant tolerance. T cell depletion is successfully employed to treat acute 
rejection and can be used in induction regimens (reviewed in (282)). T cell depletion may 




or subsets of T cells, such as CD4+ and CD8+ T cells following anti-CD4 mAb or anti-
CD8 mAb therapy, respectively.  
In the 1980‟s, Waldmann and colleagues tested a number of rat antibodies 
targeting mouse lymphocytes, all of which elicited neutralizing Ab responses except for 
anti-CD4 mAb (283). A brief course of anti-CD4 mAb in mice induced tolerance to 
aggregated human IgG (HGG), which is normally highly immunogenic in mice, but 
failed to induce tolerance toward chicken gamma-globulin or ovalbumin (283). The 
difference in these antigens was that HGG persisted, while chicken gamma-globulin and 
ovalbumin have very short half-lives. This indicated that tolerance induced by anti-CD4 
mAb was not by default, but required antigen persistence to reinforce tolerance. 
Tolerance in mice treated with anti-CD4 mAb proved to be persistent, was CD4+ T cell-
mediated, and was not reversible upon adoptive transfer naïve T cells into tolerized mice 
(284). This argued for a dominant active regulatory mechanism that did not require 
additional immunosuppression to confer antigen specific hyporesponsiveness to a new 
population of naïve cells.  
Inductive anti-CD4 mAb treatment prevents acute rejection, inhibits donor-
reactive responses and promotes tolerance in kidney, heart, and skin transplants (285-
289). Tolerance induction is primarily through CD4+ cell depletion. Anti-CD4 mAb 
(GK1.5) is a complement fixing rat IgG2b and, in vitro, has been demonstrated to lyse 
CD4+ T cells through complement-fixation (285). However, experiments in anti-CD4 
mAb treated complement component C1q-/- allograft recipients indicate that depletion 
occurs independently of C1q and the classical C pathway (285). It has been reported that 




memory CD4+ cells (290). Studies also suggest that CD4 ligation down-regulates both 
IL-2 and IL-2R expression, limiting T cell responsiveness to IL-2 (291). In addition, upon 
CD4+ T cell repopulation, one study indicates that there is a significant enhancement in 
the ratios of CD4+CD25+ and CD4+CD25+FoxP3+ T cells to CD4+ T cell in the 
periphery (292).  
 In skin transplant models, Waldmann and colleagues demonstrated that tolerance 
induced by a non-depleting anti-CD4 mAb treatment is dominant and mediated by CD4+ 
T cells (293). Adoptive transfer of naïve CD4+T cells into recipients exhibiting long-term 
allograft acceptance following inductive anti-CD4 mAb treatment, results in a spread of 
infectious tolerance to the naïve cells and no alloreactivy toward the graft is observed 
(293). It is postulated that in this model, Treg are less susceptible to apoptosis or 
inactivation in response to the anti-CD4 mAb and are able to proliferate and migrate into 
the graft in order to suppress alloreactivity. In addition, in skin transplant studies it was 
revealed that following CD4 blockade, Treg can be induced de novo through a TGFβ-
dependent mechanism, and accumulate in tolerated grafts (138). These iTreg cells 
express FoxP3+ and can actively suppress graft destruction.  
Anti-CD4 mAb treatment in vascularized mouse cardiac allograft model 
In the vascularized mouse cardiac allograft model, transient depletion of CD4+ T 
cells results in prolonged graft survival and the development of CR (232) (Figure 5). Data 
generated in this experimental model reveals a strong correlation between TGFβ-induced 
connective tissue growth factor (CTGF) (a down-stream mediator of TGFβ-induced 
fibrosis) and CR. Adenoviral gene transfer of active TGFβ into allografts, but not 





Transient depletion of recipient CD4+ T cells 
at the time of transplant promotes allograft acceptance but allows TGFβ expression within the 
graft and the progression of chronic rejection.  In contrast, anti-CD40L mAb treatment of 
transplant recipients results in prolonged allograft survival but no evidence of CR. 
 
 
CR (235). An additional cytokine, IL-6, has recently been implicated in driving fibrosis 
and hypertrophy in CR allografts in this model (294). Neutralization of IL-6 through anti-
IL-6 mAb administration or by employing IL-6 deficient mice as transplant recipients 
ameliorated cardiomyocyte hypertrophy, graft fibrosis, and improved graft function 
(294).    
Inductive anti-CD4 mAb treatment permits the CD4+ T cells to begin 
repopulating the periphery 3-4 weeks post-transplantation (285, 295, 296). As CD4+T 
cells return, donor-reactive T cells are functionally distinct from naïve cells in that these 
repopulating CD4+ exhibit a transient donor-reactive Th1 and Th2 priming that peaks 
around day 30 post-transplant (297). These graft-reactive cells progress to a 
hyporesponsive state toward the graft, but mount Th2 recall responses and demonstrate 
accelerated CR if transferred into allograft-bearing SCID mice (297). This altered 
functional T cell capacity is associated with intragraft expression of TGFβ and FoxP3. 




TGFβ may perpetuate its suppressive activities by inducing TGFβ-producing Treg (298, 
299). Indeed, flow cytometry of GICs and quantitative RT-PCR has been employed to 
detect the presence of FoxP3+ cells within the graft and an enriched population of 
intragraft Treg are detected in anti-CD4 mAb treated recipients compared to allografts 
from unmodified recipients. Maintenance of transplant tolerance and CR in anti-CD4 
mAb treated recipients is strongly associated with intragraft TGFβ and the progression of 
graft-reactive cells to an altered state of differentiation (297).  
Co-stimulatory blockade: CD40:CD40L disruption 
 In vivo co-stimulation blockade with anti-CD40L mAb has been shown to prolong 
allograft survival in several models of transplantation (reviewed in (38)). As discussed 
previously, failure to receive costimulatory signals following TCR ligation can result in T 
cell anergy or death, so inductive costimulatory blockade is a suitable therapeutic to 
selectively target donor-reactive cells prior to T cell effector function (28). The 
mechanism by which anti-CD40L mAb controls donor-reactive cells in vivo is still being 
elucidated and it is possible that this therapy has a multiple mechanisms of action.  
The graft sparing effect of CD40:CD40L blockade transcends just blocking 
interactions with CD40, and reports indicate that anti-CD40L mAb may delete T cells 
through AICD, activate CD4+ T cells to secrete immunomodulatory cytokines, and 
induce Treg development (298, 300-302). Blocking CD40:CD40L interactions inhibits 
CD4+ and CD8+ T cell proliferation and induces anergy, unless exogenous IL-2 is 
applied. In addition to anergy induction, a cell cycle-dependent donor-reactive T cell 
apoptosis in vivo due to both AICD and passive apoptosis has been reported (279). In 




autoreactive cells and knockout mice for these factors cannot maintain transplantation 
tolerance normally induced by CD40:CD40L blockade (279, 303). Anti-CD40L mAb 
also significantly inhibits alloantibody production by donor-reactive B cells due to the 
lack of T cell help (277). 
Anti-CD40L mAb treatment also affects cytokine production and upregulates 
downstream mediators to induce and maintain tolerance. CD40:CD40L blockade 
stimulates secretion of IL-10, IFNγ, and TNF but not IL-2 by CD4+ T cells in vitro 
(300). Cytokine secretion followed by apoptosis indicates early and direct effects of 
CD40:CD40L blockade on CD4+ cells (300). A deviation toward Th2 skewing has also 
been observed in CD4+ T cells in response to cross-linking of CD40L, which may, in 
fact, indicate Treg development since Treg have recently been identified to over-express 
a subset of Th2 gene transcripts in a model of skin transplant (35, 304). In addition, 
several downstream mediators, including CTLA-4, IFNγ, and heme oxygenase-1 (HO-1) 
were found to be responsible for graft survival, following CD40:CD40L blockade (38).  
In addition to deletion of autoreactive cells, transplant recipients treated with anti-
CD40L mAbs, manifest infectious tolerance, or the spread of tolerance to new groups of 
graft-reactive T cells, indicating suppression by Treg (301). It is postulated that these 
Treg may be resistant to anti-CD40L mAb therapy and would persist following graft-
reactive T cell deletion, altering the ratio between regulators and aggressors in favor of 
tolerance (301). Alternatively, potentially donor-reactive T cells that fail to undergo 
apoptosis associated with AICD may become iTreg in response to antigen recognition in 




induced by anti-CD40L mAb and DST, Treg were shown to be the essential mediators of 
tolerance (305).  
Anti-CD40L mAb treatment in vascularized mouse cardiac allograft model 
 In the mouse cardiac allograft model, prolonged allograft survival can be achieved 
by disrupting CD40-CD40L interactions (232). Allografts in mice treated with anti-
CD40L mAb remain free of CR and fail to express intragraft TGFβ (Figure 5). Gene 
transfer of active TGFβ into allografts of recipients treated with anti-CD40L mAb results 
in CR and elevated levels of the TGFβ induced downstream fibrotic factor, CTGF (232). 
A transient low but detectable Th1 and Th2 priming of donor-reactive cells are observed 
at day 10 post-transplant in anti-CD40L mAb treated recipients. However, these cells are 
eliminated since graft-reactive T cells in recipients with long-term allograft acceptance 
induced by CD40L blockade exhibit hyporesponsiveness (297). Adoptive transfer of 
splenocytes from long-term allograft recipients treated with anti-CD40L mAb into SCID 
donor-specific allograft recipients results in acute rejection mediated by a dominant Th1 
response, similar to naïve cells (297). These observations provide support that one 
mechanism by which tolerance is induced in recipients treated with anti-CD40L mAb is 
through the maintenance of potentially alloreactive T cells in a naïve state (297).  
1.9 Immunosuppressive drugs 
 Clinical immunosuppression in a transplant recipient is a balancing act between 
preventing rejection and losing protection against mutant cells and infectious agents as 
well as additional side effects described below. Immunosuppression is very intense 
immediately following transplantation but over the course of the first year diminishes as 




to the graft (306). Most acute rejection occurs in the first few months following 
transplantation and can be reversed by intensifying immunosuppression. Multiple drugs 
are administered to control transplant rejection and can be divided into 
immunosuppressive agents that inhibit of inflammation (corticosteroids) and proliferation 
(azathioprine, mycophenolate mofetil), calcineurin inhibitors (Cyclosporine and 
Tacrolimus), mTOR inhibitors (Sirolimus), and anti-lymphocyte Abs (anti-thymocyte 
globulin and OKT3) (306).   
Corticosteroids 
 In 1963, Goodwin et al. demonstrated the effect of corticosteroids on reducing 
lymphocyte counts and reversing kidney allograft rejection (307). Corticosteroids have a 
multitude of immunosuppressive effects and can 1) suppress macrophage function and 
inhibit the release of TNF-, IL-1 and IL-6; 2) inhibit T cell proliferation and induce 
apoptosis; 3) decrease MHC expression; 4) inhibit transmigration of immune cells 
through blood vessels; 5) inhibit adhesion molecule expression and 6) block the release 
of cytokines, including GM-CSF, IL-2, IL-4, IL-5, and IL-13 (306). Long-term use of 
corticosteroids can result in opportunistic infection, osteoporosis, diabetes, hypertension, 
diabetes, impaired healing of wounds, and weight gain (306).  
Azathioprine 
 The imidazole derivative, Azathioprine (AZA), was first used as a primary 
immunosuppressive agent to control kidney rejection in 1963 (308). AZA is a purine 
analogue that has anti-proliferative effects on cells, including T and B cells. AZA is 
metabolized in the liver into the active drug, 6-mercaptopurine (6-MP) (306). 6-MP is 




guanylic and adenylic acids from inosinic acid and is incorporated into DNA strands 
during replication, thereby interfering with DNA synthesis (306). In addition, TIMP acts 
in a negative feedback loop for de novo purine synthesis--a pathway that lymphocytes are 
dependant on--leading to cell cycle arrest. Major side effects of AZA include bone 
marrow suppression: leucopenia, thrombocytopenia and anemia (306).  
Mycophenolate mofetil 
 The active agent of Mycophenolate mofetil (MMF), mycophenolic acid (MPA), 
was initially isolated in 1896 from a penicillium culture (309). MMF selectively inhibits 
lymphocyte proliferation by interrupting the de novo purine synthesis pathway, which is 
essential for nucleotide synthesis since lymphocytes lack a purine salvage pathway (306).   
MPA inhibits inosine monophophate dehydrogenase (IMPDH), which is a critical 
enzyme in de novo purine synthesis, resulting in a guanine nucleotide deficiency. In 
addition to interfering specifically with lymphocyte DNA replication, MMF suppresses 
Ab induction, cytotoxic T cell differentiation, and reduces expression of adhesion 
molecules. Side effects include gastrointestinal disorders (306).  
Cyclosporine 
 In the early 1970‟s, Jean Borel screened soil samples from Wisconsin and 
Norway to identify compounds with anti-microbial or anti-fungal properties (310). The 
fungus, Tolypocladium inflatum Gams, isolated from Norweigan soil, synthesized a 
compound termed cyclosporine that was identified to be immunosuppressive (310). The 
active metabolite, Cyclosporin A (CSA), complexes with cyclophilin and this complex 
binds to and inhibits the Ca2+-dependent serine phosphatase, calcineurin (306, 311). 




dependent transcription factors, such as NFAT, which is important in the activation and 
transcription of many T cell cytokines and co-stimulatory molecules, which include IL-2, 
IFNγ, IL-4, TNF, G-CSF and CD40L (311). A major side effect associated with CSA is 
nephrotoxicity (311). 
Tacrolimus 
 Because of CSA‟s associated nephrotoxicity, Toru Kino tested Japanese soil for a 
compound more effective than CSA without the toxic side effects (306). A compound 
isolated from the bacteria, Streptomyces tsukubaenis, termed FK506 was found to be 
100X as potent as CSA (311). The active agent of Tacrolimus, FK506, binds the 
cytoplasmic FK-binding protein (FKBP). This complex interacts with calcineurin and 
mode of action of FK506 is analogous to CSA (306). Treatment of transplant patients 
with Tacrolimus results in less rejection episodes but increased toxicity compared to 
CSA. Side effects of Tacrolimus include nephrotoxicity, neurotoxicity and diabetes 
induction (306). 
Sirolimus 
 Sirolimus, also known as Rapamycin, was isolated from the actinomycete, 
Streptomyces hygroscopicus, found in soil samples from Rapa Nui, Easter Island (312). 
Similar in structure to FK506, Sirolimus also binds to FK binding protein which 
complexes with the mammalian target of rapamycin (mTor) (306). Sirolimus is capable 
of inhibiting T cell proliferation through Ca2+-dependent and independent mechanisms 
and does not affect calcineurin. Sirolimus suppresses protein synthesis in T cells and 
inhibits IL-2, IL-4 and IL-6 signaling and CD28-mediated events (306). T and B cell 




the cell cycle. Side effects associated with Sirolimus are hyperlipidemia, 
thrombocytopenia and leucopenia (306). 
Anti-lymphocyte antibodies 
 In 1960, it was observed that rabbit anti-rat lymphocyte serum prolonged skin 
graft survival in rats and upon this observation, humanized anti-lymphocyte and anti-
thymocyte globulins were designed (313). These antibodies effectively depleted the 
patient‟s lymphoid tissue. OKT3 is a humanized mouse anti-human CD3 mAb that binds 
to the CD3 chain of the TCR/CD3 complex (311). This Ab removes the TCR from the 
surface of the T cell through endocytosis or shedding, leaving the T lymphocytes 
nonfunctional and unable to reject a graft. Additional antibodies, OKT4 and OKT8, bind 
CD4+ and CD8+ T cells, respectively. Anti-thymocyte globulin (ATG) and anti-
lymphocyte globulin (ALG) deplete circulating lymphocytes (311). A major side effect of 
these antibodies is cytokine release syndrome (CRS), which commonly occurs an hour 
post injection. CRS is the result of massive release of TNF and IFNγ when T cells 
undergo OKT3 induced activation. In addition, ATG and ALG initiate xeno-antibody 
responses, also referred to as “serum sickness.” A final side effect is a significant 
impairment in cell-mediated immunity (313).  
1.10 Dissertation overview 
The purpose of these studies was to identify the role of TGFβ in graft-reactive 
cellular and humoral responses, Treg suppressor function, allograft acceptance and CR. 
Both TGF dependent and independent pathways to allograft acceptance are 




neutralization within the allograft addresses local TGF inhibition on fibrosis and 
alloreactive T and B cell responses.  
Chapter 2 describes the materials and methods employed in these studies. 
Chapter 3 addresses the requirement for T cell responsiveness to TGF in 
allograft acceptance, T and B cell hyporesponsiveness, and the development of CR. TGF 
-induced IL-17 is implicated in graft fibrosis and may represent a therapeutic target for 
preventing CR. 
Chapter 4 assesses the impact of intragraft TGFβ neutralization on CR, donor-
reactive T cell responses, and allograft acceptance employing gene transfer of decorin 
into cardiac allografts.  
Chapter 5 summarizes the findings presented herein and suggests additional 




Chapter 2: Materials and Methods 
2.1 Mice 
C57BL/6 CD4-DNR (170), C57BL/6 wild type (WT) and BALB/c mice were 
purchased from the Jackson Laboratory. CD4-DNR mice express a dominant-negative 
TGFβRII) under the direction of the mouse CD4 
promoter, which lacks a CD8 silencer. TGFβ signaling is abrogated in both CD4+ and 
CD8+ T cells in these transgenic mice. CD4-DNR were propagated by breeding C57BL/6 
WT females with CD4-DNR males. The genotyping of transgene expressing CD4-DNR 
mice was carried out using the following PCR primers: primer WT forward 
figure5‟CTAGGCCACAGAATTGAAAGATCT-3‟; primer WT reverse 5‟-
TAGGTGGAAATTCTAGCATCATCC-3‟; primer CD4-DNR transgene (TG) forward 
5‟-GCTGCACAT CGTCCTGTG-3‟; primer TG reverse 5‟-ACT TGACTGCACCGT 
TGTTG-3‟. Primers WT forward and WT reverse were used to detect the internal control, 
IL-2 (324 bp). Primers TG forward and TG reverse were used to detect the transgenic 
allele (100 bp). CD4-DNR mice exhibit an autoimmune phenotype and 
immunopathology with age, resulting in the development of multi-focal inflammation 
best characterized by inflammatory bowel disease between 3-5 months of age (170). To 
avoid potential complications of age-related autoimmunity, mice were transplanted at 6 
weeks of age and at the termination of each experiment the colons were examined 




the mice used in this study exhibited an autoimmune phenotype. IL-17-/- mice (101) were 
generated by Dr. Yoichiro Iwakura and provided by Dr. Weiping Zou in collaboration. 
All mice were housed under specific pathogen-free conditions in the Unit for Laboratory 
Animal Medicine at the University of Michigan. These experiments were approved by 
the University Committee on Use and Care of Animals at the University of Michigan. 
2.2 Culture medium 
Culture medium consisted of the following: RPMI 1640 supplemented with 2% 
FCS, 1 mM sodium pyruvate, 100 U/mL penicillin, 100 g/mL streptomyin, 1.6 mM L-
glutamine, 10 mM HEPES buffer (all from Invitrogen), 0.27 mM L-asparagine, 1.4 mM 
L-arginine HCl, 14 M folic acid, and 50 M 2-ME (all from Sigma-Aldrich). 
2.3 Vascularized cardiac transplantation 
CD4-DNR, IL-17-/-, and WT mice were transplanted with intact BALB/c cardiac 
allografts, as described (314). Briefly, the aorta and pulmonary artery of the donor heart 
were anastomosed end-to-side to the recipient‟s abdominal aorta and inferior vena cava, 
respectively. Upon perfusion with the recipient‟s blood, the transplanted heart resumes 
contraction. Graft function is monitored by abdominal palpation. 
2.4 Adenoviral-mediated transduction of cardiac allografts 
As described (315, 316), cardiac allografts were transduced by perfusion via the 
aorta with E1/E3 deleted adenoviral vectors (5 x 10
8
 pfu) encoding the rat decorin 
(AdDec) or beta-galactosidase (Adgal). AdDec was constructed in Dr. Elizabeth 
Nabel‟s lab using a cDNA kindly provided by Dr. Wayne Border (196). Following 
perfusion, grafts were recovered and placed in iced Ringer‟s for approximately 1 h prior 




of transgene expression within the cardiac allograft is patchy, and that both cardiac 
myocytes and cells of the vasculature express the transgene product (315).  
2.5 In vivo mAb treatment 
The hybridoma secreting anti-CD4 (clone GK1.5) was obtained from American 
Type Culture Collection. The hybridoma secreting anti-CD40L (clone MR1) was 
provided by Dr. Randy Noelle (Dartmouth, Lebanon, NH). Anti-CD4 and anti-CD40L 
mAb were purified and resuspended in PBS by Bio X Cell (West Lebanon, NH). Mice 
received 1 mg i.p. of anti-CD4 mAb on days -1, 0, 7 (232, 295, 296). In recipients 
transiently depleted of CD4+ T cells, CD4+ T cells begin to repopulate the periphery 3-4 
weeks post-transplantation (285). Mice received 1 mg of anti-CD40L i.p. days 0, 1, and 2 
(232). All doses are relative to day of transplant.  
2.6 Histology 
Allografts were recovered at the times indicated post-transplantation, fixed in 
formalin, and embedded in paraffin. Sections were stained with hematoxylin-eosin (H & 
E) to assess myocyte viability (presence of cross striation and myocyte nuclei), and the 
nature and intensity of graft infiltrating cells. 
2.7 Recovery of graft infiltrating cells (GIC) 
Groups of three transplanted hearts were removed, pooled, minced, and digested 
with 1 mg/mL collagenase A (Roche) for 30 min at 37ºC. Tissue debris were allowed to 
settle at 1 x g and the suspension containing GIC was harvested by pipette. RBC were 
lysed by hypotonic shock, GIC were passed though a 30-µm pore size nylon mesh, and 




2.8 ELISPOT assays for cytokine-producing cells 
ELISPOT assays were performed as previously described (317). Capture and 
detection antibodies specific for IFNγ (R4-6A2, XMG1.2), IL-4 (11B11, BVD6-24G2) 
and IL-17 (TC11-18H10.1, TC11-8H4.1) were purchased from Pharmingen (San Diego, 
CA). PVDF-backed microtiter plates (Millipore, Bedford, MA) were coated with 





 recipient splenocytes were added to the plates. After 
washing, a 1:1000 dilution of anti-biotin alkaline phosphatase (AP) conjugate (Vector 
Laboratories, Burlingame, CA) was added to IFNγ and IL-17 plates, and a 1:2000 
dilution of horseradish peroxidase-conjugated streptavidin (SA-HRP; Dako, Carpinteria, 
CA) was added to IL-4 plates. Plates were washed and spots visualized by addition of 
nitroblue tetrazolium (NBT; Biorad, Hercules, CA) / 3 bromo-4-chloro-inolyl-phosphate 
 and IL-17 plates, or 3-amino-9-ethylcarbazole (AEC; Pierce, 
Rockford, IL) to IL-4 plates. Color development continued until spots were visible and 
stopped by adding H2O. Plates were dried and spots quantified with an Immunospot 
Series 1 ELISPOT analyzer (Cellular Technology Ltd., Cleveland, OH).  
2.9 RNA isolation and RT-PCR 
Cardiac allografts were homogenized in 1 mL TRIzol® (Invitrogen Life 
Technologies, Carlsbad, CA) and RNA was isolated as per manufacturers protocol. 5 g 
of total RNA were reverse transcribed using 10X PCR buffer (Roche), 10 mM dNTPs, 
Oligo (dt), M-MLV-RT (all from Invitrogen), and RNAsin (Promega). Products were 
then cleaned with 1:1 phenol/chloroform/isoamyl (25:24:1) and re-precipitated with 7.5 




Real-time PCR was performed on cDNA using a Rotor-Gene 3000 TM (Corbett 
Life Science, CA). Primer binding to DNA was detected by SYBR Green ITM dye 
(Roche, Indianapolis, IN). Relative expression of the gene of interest was expressed as 
the comparative concentration of the gene product to the GAPDH product as calculated 
by accompanying Rotor-Gene software. Significance was determined with an unpaired 
Student t-test. 
Primer sequences: 
IL-17 sense: 5‟ GGACTCTCCACCGCAATGA 
IL-17 anti-sense: 5‟GACCAGGATCTCTTGCTGGA 
FoxP3 sense: 5‟CCAAGGTGAGCGAGTGTC 
FoxP3 anti-sense: 5‟AAGGCAGAGTCAGGAGAAGT 
Rat Decorin: 5‟ AGCATAAATATGTCCAGGTCGTC 
Rat Decorin anti-sense: 5‟GAAGTCTTCCTAGTCTGGTATGAAGG 
TGFβ sense: 5‟CCTGAGTGGCTGTCTTTTGAC 
TGFβ anti-sense: 5‟CCTGTATTCCGTCTCCTTGGT  
Collagen (pro-collagen 1a) sense: 5‟ TCCCTACTCAGCCGTCTGTGCC 
Collagen anti-sense: 5‟ AGCCCTCGCTTCCGTACTCG 
GAPDH sense: 5‟CTGGTGCTGAGTATGTCGTG 
GAPDH anti-sense: 5‟CAGTCTTCTGAGTGGCAGTG 
2.10 Donor-reactive Ab determination 
As described (285, 296, 318), P815 cells (H-2
d
) were stained for flow cytometric 
analysis using diluted (1:50) sera obtained from mice as the primary Ab, followed by 




(The Binding Site, San Diego, CA, USA) at a 1:50 dilution. Data are reported as the 
mean channel fluorescence determined on a Becton Dickinson FACSCaliber (San Jose, 
CA, USA). 
2.11 Immunohistochemistry 
To detect IgG deposition within the graft, frozen sections of grafts were fixed in 
cold acetone and incubated with 1:150 dilution of goat anti-mouse IgG-HRP (Southern 
Biotech, Birmingham, AL) followed by AEC staining (285). To detect C3d and C4d 
deposition (285), sections of paraffin embedded tissue were fixed in methanol. A 1:20 
dilution of goat anti-mouse C3d (R&D Systems, Minneapolis, MN) was added followed 
by secondary detection antibodies added as per R&D System‟s anti-goat cell and tissue 
staining kit. Slides were stained with rabbit anti-mouse C4d (kindly provided by Dr. 
William Baldwin, Cleveland Clinic) at a 1:500 dilution, followed by DAB development 
using the SuperPicTure
TM
 Polymer Detection Kit (Zymed). Specificity of staining was 
ensured by staining of native hearts. 
2.12 Morphometric analysis of cardiac allograft fibrosis and hypertrophy 
Graft fibrosis was quantified by morphometric analysis of Masson‟s trichrome 
stained tissues using iPLab software (Scanalytics Inc., Fairfax, VA) (294). Mean fibrotic 
areas were calculated from 10 to 12 areas per heart section analyzed at 200X 
magnification. A minimum of 5 individual hearts were analyzed per group. To quantify 
cardiomyocyte area as a measure of hypertrophy, digital outlines were drawn around 100 
cardiomyocytes from views of H&E stained grafts at 200X magnification. Areas within 




Frederick, MD) to measure cardiomyocyte cell size (294). Five individual hearts were 
analyzed per group. 
2.13 Statistical analysis 
Data were analyzed with GraphPad Prism 4.0c software using unpaired Student t-




Chapter 3: Role of T cell Transforming Growth Factor  Signaling and IL-17 in 




CR is the main barrier to long-term transplant survival. CR is a progressive 
disease defined by interstitial fibrosis, vascular neointimal development, and graft 
dysfunction. The underlying mechanisms responsible for CR remain poorly defined. 
TGFβ has been implicated in promoting fibrotic diseases including CR, but is beneficial 
in the transplant setting due to its immunosuppressive activities. To assess the 
requirement for T cell TGFβ signaling in allograft acceptance and the progression of CR, 
we used mice with abrogated T cell TGFβ signaling as allograft recipients. We compared 
responses from recipients that were transiently depleted of CD4+ cells (that develop CR 
and express intragraft TGFβ) to responses from mice that received anti-CD40L mAb 
therapy (that do not develop CR and do not express intragraft TGFβ). Allograft 
acceptance and suppression of graft-reactive T and B cells were independent of T cell 
TGFβ signaling in mice treated with anti-CD40L mAb. In recipients transiently depleted 
of CD4+ T cells, T cell TGFβ signaling was required for the development of fibrosis 
associated with CR, long-term graft acceptance, and suppression of graft-reactive T and 
B cell responses. Further, IL-17 was identified as a critical element in TGFβ driven 
allograft fibrosis. Thus, IL-17 may provide a therapeutic target for preventing graft 






With the advent of immunosuppressive therapies, a decline in graft loss due to 
acute rejection has established chronic allograft rejection (CR) as the leading cause of 
late graft failure (319). CR is an irreversible disease characterized by deteriorating graft 
function, interstitial fibrosis, and occlusive neointima (26, 223, 320, 321). Despite 
continued investigation, the underlying mechanisms responsible for these disease 
manifestations remain poorly defined and no therapies exist to prevent or treat CR except 
re-transplantation (322). 
The immune system evolved to combat pathogens while maintaining tolerance to 
self, and TGFβ plays a pivotal role in regulating immune responses (164). The 
importance of TGFβ in immune regulation is underscored by the severe autoimmunity 
observed in knockout mice that lack TGFβ or are unable to signal through the TGFβ 
receptor (169, 170). TGFβ controls T cell mediated self-reactivity by regulating 
lymphocyte proliferation and survival, inhibiting Th1/Th2-cell differentiation, and 
dampening effector function (reviewed in (178)). TGFβ signaling in B cells inhibits 
proliferation and survival, prevents activation, and inhibits IgG class switching (178). 
TGFβ is also critical in both the development and function of T regulatory cells (Treg) 
(172, 173, 178, 323). TGFβ signaling in Treg is essential for peripheral maintenance of 
this cell subset (164, 324) and for the induction of FoxP3 expression and Treg function in 
CD4+CD25- T cells (325).  
In addition to TGFβ‟s anti-inflammatory activities, TGFβ also mediates pro-
inflammatory as well as pro-fibrotic activities. A reciprocal developmental pathway 




association with IL-6 or IL-21 favors the commitment of CD4+ T cells to the Th17 
lineage (93, 94, 327-330). IL-17 stimulates stromal cells, such as fibroblasts, endothelial 
cells, and epithelial cells to produce IL-6, IL-8, granulocyte CSF (G-CSF), and PGE2 and 
up-regulates critical chemoattractants, such as CXCL1 and CXCL2 (91, 97, 98). IL-17 
serves to amplify the inflammatory responses and has also recently been implicated as a 
pro-fibrotic cytokine (92, 231, 331-336).  
A critical role for TGFβ in transplant acceptance has been described (337, 338), 
and early studies revealed the importance of TGFβ in donor-specific transfusions and 
allograft acceptance (339). Subsequent studies investigating skin allograft acceptance 
have also identified TGFβ as a protective factor against allograft rejection (299, 340). 
Further, transduction of cardiac allografts with active TGFβ prolongs graft survival (316) 
and is associated with the induction of graft-reactive Treg (235).  
While TGFβ mediates many beneficial anti-inflammatory activities in the immune 
system (164), we have previously reported an association between TGFβ and fibrosis 
associated with CR using the mouse vascularized cardiac allograft model (232). Intragraft 
transcript levels of TGFβ were readily detectable in the CR grafts from recipients 
transiently depleted of CD4+ T cells, but not in the grafts of anti-CD40L treated 
recipients, which remain free of CR (232). Allograft transduction with active TGFβ 
resulted in CR in anti-CD40L treated recipients that do not normally exhibit CR, but was 
not observed in TGFβ transduced syngeneic grafts. This supported a critical role for 
TGFβ and alloantigen in the progression of CR. In this study, we sought to determine the 
role of TGFβ signaling on alloreactive effector cells, Treg function, and IL-17 induction 




IL-17 deficient (IL-17-/-) mice (101) as transplant recipients. Further, we identify both 





In the mouse cardiac allograft model, prolonged allograft survival can be achieved 
by transiently depleting recipients of CD4+ cells or by disrupting CD40-CD40L 
interactions. However, these two inductive therapies differ with respect to the 
development of CR. Allografts in mice treated with anti-CD40L mAb remain free of CR, 
while grafts in mice transiently depleted of CD4+ cells develop CR, which is associated 
with intragraft expression of TGFβ (232). While graft-reactive T cells remain in a 
hyporesponsive state in both settings, recall responses of cells from these groups differ in 
that dominant Th2 responses are mounted by mice that are depleted of CD4+ cells, while 
Th1 responses are mounted by recipients given anti-CD40L mAb therapy (297). The 
current study assessed the requirement for TGFβ signaling in T cells for allograft 
acceptance, graft-reactive T and B cell hyporesponsiveness, and graft fibrosis as a 
paramater of CR. 
Effect of T cell TGFβ signaling on transplant acceptance 
TGFβ mediates beneficial immunosuppressive activities in the transplant setting 
(337-339). To assess the requirement for T cell TGFβ signaling in allograft acceptance 
and the progression of graft fibrosis associated with CR, we used CD4-DNR mice with 
abrogated T cell TGFβ signaling (170) as allograft recipients. CD4-DNR mice express a 
dominant-negative form of the human TGFβRII under the direction of the mouse CD4 




and CD8+ T cells in these transgenic mice. To rule out allo-antigen independent cellular 
infiltration and tissue damage in CD4-DNR recipients, both WT and CD4-DNR mice 
were transplanted with syngeneic grafts. Grafts from both groups functioned until the 
experiment was terminated on day 50 post-transplant (Figure 6A). Histologically, 
sygeneic grafts from both groups were free of infiltrate, exhibited minimal fibrosis, 
normal arteries and viable myocytes (data not shown). Similar observations were made in 
CD4-DNR recipients of syngeneic grafts treated with inductive CD4+ T cell depletion 
(data not shown). The results indicate that there were no differences in graft survival or 
histology between the WT and CD4-DNR recipients of syngeneic grafts ruling out non-
antigen specific inflammatory responses in graft loss in CD4-DNR mice. 
WT 
(squares and triangles) and CD4-DNR (circles and diamonds) mice were transplanted with 
allogeneic or syngeneic cardiac allografts and were either left untreated (A), given inductive anti-
CD40L mAb (B), or transiently depleted of CD4+ cells (C). Graft function was monitored by 
palpation and recipients were recovered either at the time of rejection or 50 days post-transplant. 
(D) Flow cytometric analysis of CD4+ splenocytes that were harvested from WT or CD4-DNR 
on day 20 and day 40 post-transplant. Allograft recipients were treated inductively with anti-CD4 
mAb.  
 




Due to the immunosuppressive activities of TGFβ, we predicted that CD4-DNR 
recipients would mount exacerbated rejection responses when compared to WT mice. 
Allografts in both WT and CD4-DNR recipients were acutely rejected by day 9 post-
transplant (Figure 6A) and histological examination revealed evidence of rejection (data 
not shown). While the tempo of rejection was not different between these two groups, a 
more intense infiltration of the grafts was observed in CD4-DNR recipients (total number 
of GICs per graft: WT = 0.33 x 10
6
 +/- 0.01; CD4-DNR = 1.4 x 10
6
 +/- 0.23 (p<0.01)) 
indicating that T cell TGFβ signaling dampens cell proliferation and/or cellular 
infiltration in unmodified recipients. 
Treatment of both WT and CD4-DNR recipients with inductive anti-CD40L mAb 
resulted in long-term graft survival (Figure 6B), demonstrating that allograft acceptance 
following anti-CD40L therapy is independent of TGFβ signaling in T cells. WT allograft 
recipients treated with inductive CD4+ T cell depletion also exhibited long-term graft 
survival (Figure 6C). In contrast, 90% of the allografts from CD4-DNR mice transiently 
depleted of CD4+ T cells were rejected by day 40 post-transplantation (Figure 6C). The 
majority of the allografts were rejected between days 35-40, correlating with CD4+ T cell 
repopulation of the periphery (285, 296). A greater percentage of CD4+ T cells were 
present in the spleens of CD4-DNR recipients compared to WT suggesting that TGFβ 
signaling controls CD4+ T cell proliferation in recipients transiently depleted of CD4+ T 
cells (Figure 6D). Rejection could be attenuated in CD4-DNR recipients when CD4+ T 
cells were continuously depleted by weekly injections of anti-CD4 mAb (Figure 6C). 




recipients transiently depleted of CD4+ T cells and that repopulation of CD4+ cells is 
required for rejection in CD4-DNR mice. 
-reactive Th1, Th2 and Th17 responses  
T cell TGFβ signaling inhibits differentiation of Th1 and Th2 cells through the 
suppression of T-bet/STAT4 and GATA3/NFAT (164, 178). To determine if T cell TGFβ 
signaling regulates donor-reactive cellular immune responses, we employed ELISPOT to 
quantify the number of in vivo primed donor-reactive Th1 (IFN), Th2 (IL-4) and Th17 
(IL-17) responses (Figure 7). Elevated donor-reactive Th1 responses were observed in 
unmodified WT and CD4-DNR recipients indicating acute rejection is associated with a 
dominant Th1 response (Figure 7A). While abrogation of TGFβ signaling in recipients 
did not result in elevated Th1 responses compared to WT recipients, CD4-DNR 
recipients did exhibit enhanced IL-4 priming in response to donor antigen. However, this 
was not statistically significant. Donor-reactive Th17 responses were negligible in both 
WT and CD4-DNR recipients.  
Donor-reactive Th responses were not observed in either WT or CD4-DNR 
recipients treated with anti-CD40L (Figure 7B). These findings indicate that T cell TGFβ 
signaling is not required for the suppression of donor-reactive responses (341) and is 
dispensable for allograft acceptance following anti-CD40L mAb treatment.  
As previously reported (295-297), donor-reactive Th1 and Th2 responses are 
suppressed in recipients transiently depleted of CD4+ T cells. Consistent with these 
findings, inductive anti-CD4 mAb  therapy resulted in hyporesponsiveness in WT 





WT (open bars) or CD4-DNR (shaded bars) allograft recipients were left untreated (A), treated 
with inductive anti-CD40L mAb (B), or treated with inductive anti-CD4 mAb (C). Graft function 
was monitored by palpation and recipients were recovered either at the time of rejection, 50 days 
post-transplant (for anti-CD40L mAb treated WT and CD4-DNR recipients), or 40 days post-
transplant (for anti-CD4 mAb treated WT recipients in order to directly compare to CD4-DNR 
recipients, which reject between days 35-40). At the termination of the experiment, splenocytes 
were harvested and processed for ELISPOT assays to quantify primed, donor-reactive IFN, IL-4, 
or IL-17-producing cells. Bars represent the mean number of cytokine producing cells  (+/- 
S.E.M.) from at least six recipients per group.  
 
 
donor-reactive Th1 and Th2 responses were detected in the CD4-DNR recipients 
transiently depleted of CD4+ T cells (Figure 7C).These data indicate that TGFβ plays a 
pivotal role in suppressing immune responses and in maintaining allograft acceptance in 
recipients initially depleted of CD4+ T cells.  




Cardiac fibrosis is reduced in mice with abrogated T cell TGFβ signaling 
TGFβ has been strongly implicated in many fibrotic diseases (231, 342), 
including CR (233, 320, 321, 343). To investigate the relationship between T cell TGFβ 
signaling and the development of graft fibrosis as a measure of CR, quantitative 
morphometric trichrome analysis was employed to evaluate allograft fibrosis in WT and 
CD4-DNR recipients treated with inductive anti-CD40L or anti-CD4 mAb. Allografts 
from WT and CD4-DNR recipients treated with inductive anti-CD40L mAb revealed 
minimal fibrosis (Figure 8A and 8B). Allografts from WT recipients transiently depleted 
of CD4+ T cells revealed significant fibrosis compared to allografts from CD4-DNR 
(A) Sections of grafts from recipients treated with inductive anti-CD40L (day 50 post-transplant) 
or anti-CD4 mAb (between days 35-40 post-transplant due to rejection in CD4-DNR recipients) 
were stained with Masson‟s trichrome, which stains fibrotic tissue blue. Frames are of grafts from 
WT and CD4-DNR recipients and are representative of at least 6 anti-CD40L mAb treated mice 
and 6-8 anti-CD4-treated mice. 200X magnification. (B) Quantification of mean fibrotic area by 
morphometric analysis in anti-CD40L and (C) anti-CD4 mAb treated WT and CD4-DNR 
recipients. Bars represent the average percentage (+/- S.E.M.) of graft area positive for fibrosis in 
5 anti-CD40L treated recipients and 6 anti-CD4 treated recipients. WT (open bars) and CD4-
DNR (shaded bars). 






recipients (Figure 8A and 8C). These findings indicate that in recipients transiently 
depleted of CD4+ cells, allograft fibrosis is dependent on T cell TGFβ signaling.  
Donor-reactive IgG production in WT and CD4-DNR recipients 
Since donor-reactive antibodies have been implicated in both acute and chronic 
rejection (344, 345), we analyzed WT and CD4-DNR recipients for donor-reactive IgG 




were obtained from WT (open bars) or CD4-DNR (shaded bars) allograft recipients that were left 
untreated (A), treated with inductive anti-CD40L mAb (B), or treated with inductive anti-CD4 
mAb (C). Sera were obtained at the time of rejection for unmodified recipients), 50 days post-
transplant (for anti-CD40L mAb treated WT and CD4-DNR recipients), or 40 days post-
transplant (for anti-CD4 mAb treated WT recipients). P815 (H-2
d
) cells were incubated with 1:50 
dilution of sera and bound donor-reactive Ab were detected by incubation with FITC-tagged anti-
IgG, anti-IgG1 or anti-IgG2a Abs. The mean channel fluorescence is indicative of the relative 
amount of donor-reactive antibodies. Bars represent the average mean channel fluorescence of at 
least 6 WT and 6 CD4-DNR recipient samples (+/- S.E.M.). IgG1 and IgG2a donor-reactive Ab 
levels were analyzed in anti-CD4 mAb treated WT and CD4-DNR recipients (D). 
 




recipients exhibited comparable donor-reactive IgG production (Figure 9A). These results 
indicate that TGFβ signaling does not overtly influence IgG alloantibody production in 
unmodified recipients. It is well established that CD40-CD40L interactions are critical for 
Ab isotype switch (346). Consistent with these findings, both WT and CD4-DNR 
recipients treated with anti-CD40L mAb did not generate donor-reactive IgG production 
compared to unmodified recipients (Figure 9B). Hence, CD40-CD40L interactions are 
required for IgG isotype switching in the presence or absence of TGFβ signaling in T 
cells.  
CD4-DNR recipients inductively depleted of CD4+ T cells produced significantly 
elevated levels of donor-reactive IgG compared to WT controls (Figure 9C). To further 
characterize the donor-reactive Ab production in these recipients, both Th1- and Th2- 
dependent IgG2a and IgG1 isotypes were measured (347). Consistent with an increase in 
total IgG level, the CD4-DNR recipients exhibited significantly elevated levels of both 
IgG1 and IgG2a alloAb production compared to WT recipients (Figure 9D). Collectively, 
these findings demonstrate that in the absence of TGFβ signaling, T cells acquire effector 
functions, secrete both Th1 and Th2 cytokines, and provide help for alloreactive B cells 
in recipients transiently depleted of CD4+ T cells. 
Evidence of Ab-mediated rejection in CD4-DNR recipients treated with anti-CD4 mAb 
The diagnostic criteria for Ab-mediated rejection include histologic evidence of 
acute tissue injury, serologic evidence of circulating donor-reactive antibodies, and the 
deposition of complement C3d and C4d within allografts (reviewed in (77, 219, 344)). 
Hence, we investigated the deposition of IgG and C3d and C4d within the grafts from 





WT (left column) or CD4-DNR (right column) allograft recipients were treated with inductive 
anti-CD4 mAb therapy. Grafts were recovered at either the time of rejection or 40 days after 
transplantation. Graft sections were fixed and incubated with goat anti-mouse IgG (A) or the goat 
anti-mouse C3d or C4d (B) followed by development with 3-amino-9-ethylcarbazole or DAB to 
visualize mouse Ab and complement deposition. Results are representative of grafts from 6-10 
recipients. Magnification, 400X (A) and 200X (B). 
 
 
IgG staining was localized mainly to the capillaries and arteries of allografts from CD4-
DNR recipients, while allografts from WT recipients were free of IgG deposition (Figure 
10A). Further, both C3d and C4d were deposited within the vasculature structures of 
allografts from CD4-DNR recipients, but were not present in control allografts (Figure 
10B). These data indicate that in recipients transiently depleted of CD4+ T cells, antibody 
mediated rejection of allografts occurs when T cells are unresponsive to TGFβ. 
Anti-CD4 treated CD4-DNR recipients exhibit reduced intragraft FoxP3 and IL-17 
levels compared to WT controls 
 
TGFβ induces expression of FoxP3 (348), leading to the differentiation of CD4+CD25+ 
Treg cells from CD4+CD25- T cells (138, 325, 349). However, a dichotomy exists in 
which TGFβ in the context of IL-6 or IL-21 promotes pathogenic Th17 cell development 
(93, 94, 326-329). To investigate the role of TGFβ signaling in Treg and Th17 induction 
and the contribution of these subsets in CR, we assessed intragraft FoxP3 and IL-17 
transcript levels from WT and CD4-DNR recipients inductively depleted of CD4+ T cells 
 














RNA was harvested from allografts of WT and CD4-DNR recipient transiently depleted of CD4+ 
T cells. Intragraft transcript levels of FoxP3 and IL-17 were assessed by real-time RT-PCR. 
Allografts were recovered between days 35-40 post-transplant. Bars depict the means of RNA 
expression from 6 WT and 9 CD4-DNR grafts. 
 
and showed that allografts from the CD4-DNR recipients exhibited significantly reduced 
intragraft FoxP3 gene expression compared to WT (Figure 11). This may indicate a 
failure to induce Treg from naïve CD4+ T cells in the absence of T cell TGFβ signaling, 
poor maintenance of peripheral Treg, and/or reduced Treg trafficking into the graft  
(reviewed in (298)). In addition, intragraft IL-17 was detected in allografts from WT but 
not CD4-DNR recipients (Figure 11). IL-17 was not detected by ELISPOT in the spleens 
of the WT mice (Figure 7), which may suggest a compartmentalized immune response 
against donor antigen. Indeed, similar polarization of Th17 responses solely within target 
tissue has been observed in murine models of allergic lung disease and hypersentitivity 
pneumonitis and lung fibrosis (336, 350). IL-17 is best recognized as a cytokine that 
mobilizes neutrophils and coordinates local tissue inflammation through the induction of 
various pro-inflammatory cytokines (91, 97). Numerous recent reports implicate IL-17 as 
a pro-fibrotic cytokine in the context of T cell dependent fibrosis (92, 331-336, 351), 
capable of inducing fibroblast proliferation and collagen deposition in cardiac tissue (92). 
Our observation that allografts from CD4-DNR recipients treated with anti-CD4 
Figure 11: Reduction of TGFβ-dependent intragraft gene expression from recipients 




exhibited minimal fibrosis (Figure 8) led us to hypothesize that IL-17 plays a pro-fibrotic 
role in CR. 
Allograft fibrosis is reduced in anti-CD4 mAb treated IL-17-/- recipients 
To investigate the role of IL-17 production in fibrosis associated with CR, IL-17  
-/- mice (101) were used as transplant recipients. Both WT and IL-17-/- allograft 
recipients treated with inductive anti-CD4 mAb therapy exhibited long-term graft 
survival, while unmodified recipients rejected their grafts by day 9 post-transplant 
(Figure 12A). In IL-17-/- recipients transiently depleted of CD4+ T cells, fibrosis was 
markedly reduced relative to WT counterparts (Figure 12B and 12C). This reduction of 
allograft fibrosis in IL-17-/- recipients implicates IL-17 as a cytokine responsible for 
TGFβ-mediated fibrosis and CR. 
To investigate the effect of IL-17 deficiency on intragraft gene expression, we 
assessed both IL-17 and FoxP3 transcript levels from WT and IL-17-/- recipients that 
were transiently depleted of CD4+ t cells. Allografts from IL-17-/- recipients exhibited 
comparable FoxP3 gene expression to WT counterparts, while IL-17 transcripts were not 
detected in the IL-17-/- recipients (Figure 12D). These results suggest that reduced  
fibrosis in IL-17-/- recipients transiently depleted of CD4+ T cells is not a result of 





WT (squares) and IL-17-/- (circles) mice were transplanted with BALB/c cardiac allografts and 
were either left untreated (closed symbols) or transiently depleted of CD4+ cells (open symbols). 
Graft function was monitored by palpation. Unmodified recipients were recovered at the time of 
rejection, while inductive anti-CD4 mAb treated recipients were harvested at day 50 post-
transplantation. Numbers in parentheses represent the number of recipients in each group (A). 
Sections of grafts from recipients treated with inductive anti-CD4 mAb therapy (day 50 post-
transplant) were stained with Masson‟s trichrome stain. Frames are of grafts from WT and IL-17-
/- recipients and are representative of at least 6 WT and 9 IL-17-/- recipient allografts. 200X 
magnification (B). Quantification of fibrosis by morphometric analysis. Bars represent the 
average percentage (+/- S.E.M.) of graft area positive for fibrosis in at least 5 WT and IL-17-/- 
recipients treated with anti-CD4 mAb. WT (open bars) and IL-17-/- (closed bars) (C). On day 50 
post-transplant, RNA was harvested from allografts of WT and IL-17-/- recipients transiently 
depleted of CD4+ T cells. Intragraft transcript levels of FoxP3 and IL-17 were assessed by 




We have previously reported an association between TGFβ and graft fibrosis 
associated with CR using the mouse vascularized cardiac model (232). Intragraft 
transcript levels of TGFβ are readily detectable in the CR grafts from recipients 




transiently depleted of CD4+ T cells, but not in the grafts of anti-CD40L treated 
recipients, which remain free of CR. In the current study, we used inductive anti-CD4 or 
anti-CD40L mAb therapy and CD4-DNR recipients to evaluate the role of T cell TGFβ 
signaling in graft acceptance and the progression of fibrosis associated with CR. 
Collectively, our data suggests that in WT allograft recipients transiently depleted of 
CD4+ cells, allograft acceptance, T and B cell hyporesponsiveness, and fibrosis of the 
graft are dependent on TGFβ signaling in T cells. We further demonstrate that IL-17 is 
involved in the development of graft fibrosis in recipients transiently depleted of CD4+ T 
cells. 
T cell TGFβ signaling is not required for long term allograft acceptance following 
anti-CD40L therapy (Figure 6). It is not fully understood how blockade of CD40L results 
in allograft acceptance, but a number of mechanisms, including donor-reactive T cell 
anergy and/or deletion, and the induction of Treg have been proposed (298, 305). We 
have reported that anti-CD40L mAb therapy allows for a transient appearance of primed 
donor-reactive cells (297). Hence, it is possible that these primed T cells express CD40L, 
which targets these cells for deletion and/or silencing by anti-CD40L mAb therapy. Our 
study demonstrates that these processes do not require T cell TGFβ signaling.  
In recipients transiently depleted of CD4+ T cells, our findings support a TGFβ-
dependent mechanism of graft acceptance. Inductive anti-CD4 mAb treatment of 
recipients results in transient depletion of CD4+ T cells at the time of transplant (285, 
295, 296). CD4+ T cells begin to repopulate the periphery 3-4 weeks post-
transplantation. As CD4+ T cells return, donor-reactive T cells are functionally distinct 




mount Th2 recall responses (297). This altered functional T cell capacity is associated 
with intragraft expression of TGFβ. Inductive anti-CD4 mAb treatment of CD4-DNR 
recipients results in allograft rejection between day 35-40 post-transplantation (Figure 6). 
Th1 and Th2 were maintained in a quiescent state in WT recipients transiently depleted 
of CD4+ cells (Figure 7). In contrast, CD4-DNR recipients treated with inductive anti-
CD4 mAb mount donor-reactive Th1 and Th2 responses, revealing that the induction of 
hyporesponsiveness requires that T cells be responsive to TGFβ (Figure 7). Repopulation 
of CD4+ T cells in the periphery is required for rejection in that CD4-DNR transplant 
recipients that are continuously depleted of CD4+ T cells did not reject their grafts 
(Figure 6) and did not mount Th1 and Th2 responses (data not shown). These 
observations support an essential role for TGFβ in cellular hyporesponsiveness and 
allograft acceptance in recipients inductively depleted of CD4+ T cells. 
In the absence of TGFβ signaling, T cells differentiate into effector cells, secrete 
cytokines and provide help to B cells in CD4-DNR recipients transiently depleted of 
CD4+ cells. CD4-DNR recipients transiently depleted of CD4+ cells mounted 
significantly elevated donor-reactive alloantibody levels of both Th2 induced non-
complement fixing, IgG1, and Th1 induced complement fixing, IgG2a, compared to wild 
type controls (Figure 9) (352). Both subclassses have been documented to synergize to 
cause rejection of cardiac allografts (352). IgG and complement split product C3d and 
C4d capillary deposition in both human and mouse myocardium is significantly 
associated with graft loss (353) and these products were detected in the vessels and 
surrounding the cardiac myocytes in the CD4-DNR recipient allografts that were rejected 




responses and provide help to activate alloreactive B cells in recipients inductively 
depleted of CD4+ T cells. 
Donor-specific hyporesponsiveness is observed in both human and mouse 
transplant recipients that exhibit prolonged allograft acceptance (138, 270, 354). In many 
of these studies, allograft acceptance is strongly associated with Treg infiltration into the 
graft as detected by high FoxP3 transcript levels (138, 154, 270, 354). Treg are believed 
to play a critical role within allografts by inhibiting alloreactive T cell responses (270). 
Studies in skin allograft models reveal Treg enrichment in accepted grafts (355) is 
dependent on TGFβ and that this cytokine is important for long-term acceptance (138, 
299). Consistent with these observations, inductive anti-CD4 mAb treatment of WT 
recipients exhibit enhanced intragraft FoxP3 transcript levels compared to CD4-DNR 
(Figure 11). In CD4-DNR recipients transiently depleted of CD4+ T cells, reduced FoxP3 
expression may indicate impaired maintenance of peripheral Treg, reduced Treg 
localization within the graft, or a failure in Treg induction (reviewed in (298)). Donor-
reactive Th responses observed in CD4-DNR recipients may result from decreased 
induction of Treg and/or the failure of Treg to control effector cells in the absence of 
TGFβ signaling (356). Our data suggest an active regulatory mechanism in which Treg 
migration into the grafts (Figure 11) and inhibition of alloreactive responses (Figure 7) 
require T cell TGFβ signaling. 
While functional T cell TGFβ signaling prevented allograft rejection in recipients 
inductively depleted of CD4+ T cells, it promoted fibrosis associated with CR (Figure 8). 
In contrast, T cell unresponsiveness to TGFβ resulted in minimal fibrosis of grafts 




contributor to the development of fibrosis (233, 357), but we have observed that gene 
transfer of TGFβ in syngeneic grafts fail to develop CR (232). Fibrosis was observed 
only in allografts that adenovirally expressed TGFβ and were transplanted into anti-
CD40L recipients (232). This indicates that TGFβ alone is insufficient to induce fibrosis 
of the graft, and that alloantigen and elements of the immune system are required for 
fibrosis induction.  
As T cells infiltrate the allograft and respond to TGFβ, they secrete multiple 
cytokines, which may influence the local environment to become pro-fibrotic. One 
TGFβ-induced cytokine that could potentially mediate fibrosis in this setting is IL-17 (92, 
331). IL-17 is important in coordinating local tissue inflammation through the induction 
of various pro-inflammatory cytokines (91, 97). IL-17 has also been implicated as a 
contributor to fibrosis in a number of diseases (231, 332-334, 336). Allografts from IL-
17-/- recipients transiently depleted of CD4+ T cells showed a significant reduction in 
fibrosis relative to their WT counterparts (Figure 12). These findings are consistent with 
TGFβ induced IL-17 promoting interstitial fibrosis in CR allografts. 
 IL-17 may induce collagen deposition within CR allografts through multiple 
mechanisms. IL-17 upregulates collagen gene expression in primary mouse cardiac 
fibroblasts (92). Indirectly, IL-17 induces the production of IL-6 (91, 97), which 
enhances the accumulation of collagen (358-360). IL-17 may also play a role in fibrosis 
by acting as a potent pro-inflammatory cytokine that induces endothelial cells and 
fibroblasts to secrete additional pro-inflammatory cytokines and chemokines (91, 97). 




resulting in myocardial damage and extracellular matrix remodeling that favors fibrosis 
(321). 
 In summary, TGFβ is critical for the induction of fibrosis in this model of CR and 
in a number of fibrotic diseases, including diabetic nephropathy, rheumatoid arthritis, 
myocarditis, Crohn‟s disease and radiation-induced fibrosis (reviewed in (231)). As in 
most immune-mediated diseases, TGFβ can have both exacerbating and ameliorating 
actions making global inhibition of TGFβ unacceptable and local targeting of TGFβ or its 
downstream mediators an attractive therapy. This is evident in recipients transiently 
depleted of CD4+ cells in which T cell responsiveness to TGFβ is critical in maintaining 
alloreactive T cells in a hyporesponsive state. Our findings that TGFβ in CR grafts 
correlates with localized Th17 induction supports findings in other chronic inflammatory 
diseases (231) and provides a therapeutic target for preventing CR, while sparing the 






Chapter 4: Transforming Growth Factor β Neutralization within Cardiac Allografts 
by Decorin Gene Transfer Attenuates Chronic Rejection 
 
4.1 Abstract 
CR is the leading cause of late graft failure following organ transplantation. CR is 
a progressive disease, characterized by deteriorating graft function, interstitial fibrosis, 
cardiac hypertrophy and occlusive neointima development known for its 
immunosuppressive qualities, plays a beneficial role in the transplant setting by 
maintaining alloreactive T cells in a hyporesponsive state, but has also been implicated in 
promoting graft fibrosis and CR. In the mouse vascularized cardiac allograft model, 
transient depletion of CD4+ cells promotes graft survival but leads to CR, which is 
associated with intragraft TGFβ expression. Decorin, an extracellular matrix protein, 
inhibits both TGFβ bioactivity and gene expression. In this study, gene transfer of 
decorin into cardiac allografts was employed to assess the impact of intragraft TGFβ 
neutralization on CR, systemic donor-reactive T cell responses, and allograft acceptance. 
Decorin gene transfer and neutralization of TGFβ in cardiac allografts significantly 
attenuated interstitial fibrosis, cardiac hypertrophy and improved graft function, but did 
not result in systemic donor-reactive T cell responses. Thus, donor-reactive T and B cells 
remained in a hyporesponsive state. These findings indicate that neutralizing intragraft 






 The accepted treatment for end-stage heart failure failure is transplantation (239). 
Immunosuppressive therapies diminish the incidence of graft loss due to acute graft 
rejection, leaving chronic rejection (CR)
 
as the main impediment to long-term transplant 
survival (361). CR in cardiac allografts is characterized by interstitial fibrosis, vascular 
occlusion, cardiac hypertrophy and progressive dysfunction of the graft (224, 228, 321). 
The cellular mechanisms and cascade of events that lead to CR remains poorly defined 
and no effective therapies exist except retransplantation.   
 Transforming growth factor β (TGFβ) is a widely expressed cytokine that exerts 
pleiotropic effects on cell proliferation, migration, differentiation and survival (reviewed 
in (164)). TGFβ contributes to multiple biological processes, including tumorigenesis, 
development, wound healing, fibrosis and suppression of immune responses (164). The 
importance of TGFβ as an immune regulator was demonstrated in TGFβ deficient mice, 
which manifest a severe autoimmune phenotype that results in death at 3-4 weeks of age 
(169, 362).  TGFβ controls T cell proliferation and survival and acts to inhibit Th1/Th2 
differentiation and effector function (164, 178). B cells respond to TGFβ with decreased 
proliferation, survival and activation (363). TGFβ is also a critical cytokine in T 
regulatory cell (Treg) development and function (172, 173, 178). The Treg lineage-
specific transcription factor, FoxP3, is induced by TGFβ, and results in the conversion of 
CD4+CD25- T cells into Treg (113). Furthermore, TGFβ signaling in Treg is essential for 
peripheral maintenance of this cell subset (164, 324). 
 TGFβ also contributes to wound healing and tissue repair (342).  During normal 




act in concert to increase extra-cellular matrix (ECM) deposition, decrease matrix 
degradation, and restore normal tissue composition (357). While TGFβ is critical in 
wound healing and tissue repair, enhanced and prolonged TGFβ production is detrimental 
and observed in a number of fibrotic diseases, including pulmonary fibrosis (364), 
glomerulonephrtitis (365), scleroderma (366), and CR (232, 233).   
 Decorin, an ECM protein and member of the small leucine rich proteoglycan 
family, plays a role in TGFβ regulation (194). The core protein of decorin binds the 
active form of TGFβ, thereby inhibiting TGFβ‟s interaction with its receptor and 
sequestering the cytokine to the ECM (188, 193). In addition to inhibiting TGFβ‟s 
bioactivity, decorin negatively impacts TGFβ gene expression (195, 196). Decorin gene 
transfer ameliorated TGFβ-mediated fibrosis in a glomerulonephritis model (196) and in 
a pulmonary fibrosis model (367). 
 TGFβ mediates many beneficial anti-inflammatory effects in the transplant setting 
(299, 339) and we have previously reported an association with TGFβ and CR using the 
mouse vascularized cardiac allograft model (232). Intragraft TGFβ levels are readily 
detectable in the CR grafts from recipients transiently depleted of CD4+ T cells, but not 
in the grafts of anti-CD40L treated recipients, which remain free of CR. Adenoviral-
mediated gene transfer of the active form of TGFβ into allografts induces fibrosis and 
results in CR in recipients treated with anti-CD40L that do not normally exhibit CR 
(232). This supports a critical role for TGFβ in the progression of CR. 
 In recipients transiently depleted of CD4+ T cells, CD4+ T cells begin to 
repopulate the periphery 3-4 weeks post-transplantation (285, 295, 296). Donor-reactive 




CD4+ are hyporesponsive toward the graft but mount Th2 recall responses (297). The 
importance of TGFβ in allograft acceptance and suppression of graft-reactive T and B 
cells was revealed in transplant experiments employing mice with a dominant negative 
TGFRII transgene (CD4-DNR) (Faust et al., submitted), which render the animals 
unresponsive to T cell TGFβ signaling (170). Transient CD4+ T cell depletion of CD4-
DNR recipients resulted in both alloreactive cellular and humoral responses, which 
remained hyporesponsive in wild type (WT) recipients indicating that TGF is critical to 
suppression of T and B cell responses in this system. Graft rejection in these recipients 
correlated with CD4+ T cell repopulation of the periphery (Faust et al., submitted).  
These studies revealed that anti-CD4 mAb treatment is a TGFβ dependent model of 
allograft acceptance and that IL-17 is a critical element in TGF driven fibrosis (Faust et 
al., submitted).           
   In this study, we employed decorin gene transfer into cardiac allografts to assess 
the impact of intragraft TGFβ neutralization on CR, graft function, donor-reactive T and 
B cell responses, and allograft acceptance. We demonstrate that neutralizing intragraft 
TGFβ inhibits the cytokine‟s fibrotic activities, but does not reverse its beneficial 




Prolonged allograft survival can be accomplished in the mouse cardiac allograft 
model by depleting CD4+ T cells transiently at the time of transplant. However, 




is associated with intragraft TGFβ expression (232). TGFβ is beneficial in the transplant 
setting, and has been associated with the progression of donor-reactive T and B cells to a 
hyporesponsive state in recipients treated with anti-CD4 mAb ((297), Faust et al., 
submitted). Conversely, T cell responsiveness to TGFβ can be deleterious for the graft by 
inducing fibrosis (Faust et al., submitted). Therefore, we explored the impact of local 
TGFβ neutralization employing decorin gene transfer into the allografts. We assessed the 
impact of intragraft TGFβ neutralization on allograft acceptance, graft function, T and B 
cell hyporesponsiveness and CR.  
Decorin gene transfer into cardiac allografts 
Prior studies utilizing adenoviral transduction of allografts revealed long-term 
transgene expression and negligible off-target tissue effects (315). To evaluate efficacy of 
decorin gene transfer, allografts were transduced with adenoviral vectors that encode rat 
decorin (AdDec) or βgal (Adβgal) and transplanted into recipients treated with inductive 
anti-CD4 mAb. Functioning allografts were harvested on day 7, day 14 and day 50 post-
transplant (Figure 13). Employing rat decorin specific primers and quantitative RT-PCR, 
we verified that over-expression of rat decorin was detected predominantly within the 
cardiac allografts at day 7 and day 14 and not within non-target tissue, such as the spleen 
(Figure 13A). In addition, long-term rat decorin gene expression was detected in the 
AdDec infected allografts and not in the βgal controls at day 50 post-transplant (Figure 
13B). These results demonstrate the efficacy and tissue localization of decorin gene 






BALB/c allografts were transduced 
with AdDec or Adβgal and transplanted into C57BL/6 mice that were given inductive anti-CD4 
therapy on days -1, 0, and 7 relative to transplant. Spleens and allografts were recovered on day 7 
(light shaded bars) and day 14 (dark shaded bars) for AdDec transduced allografts (A). 
Functioning allografts were recovered on day 50 post-transplant for Adβgal (open bars) and 
AdDec (shaded bars) transduced allografts (B). Rat decorin expression relative to GAPDH was 
assessed by real-time RT-PCR from a minimum of 4 Adβgal (open bars) or 4 AdDec (shaded 
bars) transduced allografts (+/- S.E.M.). 
 
 
Intragraft TGFβ neutralization by decorin gene transfer does not reverse T and B cell 
hyporesponsiveness in recipients treated with anti-CD4 mAb 
While TGFβ is a known pro-fibrotic cytokine (368) it also has beneficial anti-
inflammatory effects in the transplant setting and is frequently observed within accepted 
grafts (299, 337-339). Since TGFβ is critical in controlling donor-reactive responses 
following transient CD4+ T cell depletion (Faust et al., submitted), it was possible that 
intragraft neutralization of TGFβ might reverse immune hyporesponsiveness if decorin 
acted beyond the local confines of the allograft and inhibited TGF systemically (196). 
To determine if localized TGFβ neutralization within the allografts affected systemic 
donor-reactive immune responses, ELISPOT was employed to quantify the number of in 
vivo primed donor-reactive Th1 (IFN), Th2 (IL-4) and Th17 (IL-17) responses (Figure 
14A). Gene transfer of βgal or decorin to allografts resulted in negligible T cell responses 
compared to untreated transplant recipients, indicating that TGFβ neutralization within 




(A) On day 50 post-transplantation, splenocytes from Adβgal or AdDec transduced recipients 
were processed for ELISPOT assays to quantify primed, donor-reactive IFNγ, IL-4 or IL-17-
producing cells. C57BL/6 recipients of BALB/c allografts that received no treatment (striped 
bars) acted as positive controls and splenocytes were harvested at the time of rejection. Bars 
represent the average number of spot forming cells (+/- S.E.M.). Numbers in parentheses 
represent the number of recipients in each group. (B) Fifty days post-transplant, sera were 
obtained from recipients transduced with Adβgal (open bars) or AdDec (shaded bars) and treated 
with inductive anti-CD4 mAb. P815 (H-2
d
) cells were incubated with sera and bound donor-
reactive Ab was detected by incubation with FITC-tagged anti-IgM or anti-IgG Abs. The mean 
channel fluorescence is indicative of the relative amount of donor-reactive Abs. Bars represent 




cardiac allografts did not reverse graft-reactive T cell hyporesponsiveness in recipients 
depleted of CD4+ T cells (Figure 14A). In addition, cardiac allograft contractions were 
noticeably stronger in AdDec transduced allografts when compared to βgal controls. 
These data demonstrate that intragraft inhibition of TGFβ had a beneficial effect on graft 





function and did not reverse systemic donor-reactive T cell hyporesponsiveness normally 
observed in anti-CD4 mAb treated recipients 
TGFβ also inhibits B cell responses by affecting B cell proliferation, survival 
signals, activation, and IgG class switching (164).  In CD4-DNR recipients treated with 
anti-CD4 mAb, T cells differentiate into effector cells and provide help to B cells, which 
produce donor-reactive IgG (Faust et al., submitted). To examine the effect of intragraft 
decorin over-expression on donor-reactive antibody, we quantified donor-reactive IgM 
and IgG production by flow cytometry (Figure 14B).  No difference in alloantibody 
production was observed in recipients whose allografts express decorin or the βgal. This 
demonstrates that B cell hyporesponsiveness is also not reversed in recipients that 
overexpress decorin within their grafts. This further indicates that there are no systemic 
effects on the alloreactive immune responses by local TGF neutralization. 
Effect of intragraft decorin gene transfer on TGFβ-induced gene expression  
TGFβ is a pleiotropic cytokine that exerts a variety of effects on many different 
cell types.  A reciprocal developmental pathway exists for the generation of pathogenic 
effector Th17 cells and Treg in response to TGFβ, with IL-6 being the co-factor required 
for Th17 induction (93, 94, 327). In addition, TGFβ induces cardiac fibroblasts to 
differentiate into myofibroblasts, which produce significant amounts of collagen and 
contribute to fibrosis (368). To assay for the effect of decorin on TGFβ-induced genes 
such as TGFβ, collagen A1, FoxP3 and IL-17, RNA was isolated from the allografts and 
quantitative RT-PCR was performed (Figure 15). 
In recipients transduced with AdDec, intragraft TGFβ (p<0.05), collagen A1 




















from grafts of recipients transiently depleted of CD4+ T cells and transduced with Adβgal or 
AdDec were recovered 50 days post-transplant. Intragraft expression of (A) TGFβ, (B) collagen 
A1, (C) IL-17 and (D) FoxP3 relative to GAPDH was assessed by real-time RT-PCR. Bars depict 
the means of RNA expression from 9 Adβgal or 9 AdDec transduced allografts.  
 
control allografts (Figure 15A-D). In contrast, intragraft FoxP3 expression was 
comparable between AdDec and Adgal transduced allografts. These observations 
indicate that localized TGFβ neutralization by decorin can significantly decrease gene 
expression associated with fibrosis, but does not affect FoxP3 expression. This data 
suggest Th17 polarization occurs within the site of inflammation--the graft--while Treg 
induction and maintenance occurs systemically in the secondary lymphoid tissues (147).       
Intragraft TGFβ neutralization significantly attenuates graft fibrosis and hypertrophy 
To investigate the effect of localized TGFβ neutralization on graft fibrosis, 




quantitative morphometric trichrome analysis was performed (Figure 16). Assessment of 






















(A) Sections of grafts from recipients transiently depleted of CD4+ T cells and transduced with 
Adβgal or AdDec were stained with Masson‟s trichrome stain on day 50 post-transplant. Fibrotic 
tissue appears blue. Magnification, 200X. (B) Morphometric analysis of trichrome staining. Bars 
represent the average percentage of (+/- S.E.M.) of graft area positive for fibrotic tissue in 9 
Adβgal (open bars) or 9 AdDec (shaded bars) transduced recipients. (C) Cardiomyocyte area 
quantification of groups described in (A). Bars represent mean (+/- S.E.M.) of area measurements 
from 100 cardiomyocytes per allograft at 200X magnification. Five individual hearts were 
analyzed per group. 





reduction of fibrosis compared to control grafts (p<0.01) (Figure 16A and 16B). These 
data indicate that TGFβ promotes cardiac fibrosis and that localized neutralization of 
TGFβ can significantly attenuate CR. 
  Cardiac hypertrophy is defined as an increase in the heart mass (369). An increase 
in the size of the cardiac myocytes, as opposed to the number, is the primary basis of 
cardiac hypertrophy (369). TGFβ is critical in driving this process (reviewed in (370)). 
An upregulation of TGFβ in cardiac tissue increases cardiomyocyte size and leads to 
cardiac dysfunction (370-372). To evaluate the effect of intragraft TGF neutralization 
on cardiac hypertrophy, cardiomyocyte cell size was measured employing histologic 
analysis (294). Reduced cardiac hypertrophy was observed in AdDec transduced grafts 
(Figure 16C). These findings indicate that intragraft TGF correlates with both fibrosis 




 CR is an intractable disease characterized by interstitial fibrosis, occlusive 
neointima development, and graft dysfunction (224, 228, 321). The etiology of CR is 
role in the transplant setting because of its immunsuppressive qualities (299, 339), but 
has also been implicated in promoting graft fibrosis and CR (320, 343). In the mouse 
vascularized cardiac model, we have previously reported an association between TGFβ 
and CR (232). Intragraft TGFβ transcript levels were readily detected in the CR grafts 




treated recipients, which remain free of CR (232), suggesting the importance of TGFβ in 
this pathology. In this study, we employed decorin gene transfer and local neutralization 
of TGFβ in cardiac allografts to assess the impact of intragraft TGFβ neutralization on 
allograft acceptance, T and B cell hyporesponsiveness and CR. We demonstrate that local 
neutralization of TGFβ in cardiac allografts significantly attenuated interstitial fibrosis 
and improved graft function, but did not reverse the hyporeactive state of donor-reactive 
T or B cells. 
 Intragraft transcript levels of TGFβ are frequently detected in accepted grafts, 
including the cardiac allografts from inductive CD4+ T cell depleted recipients. TGFβ 
expression is believed to promote graft survival through the induction of Treg, which 
control graft-reactive Th1 and Th2 responses (299, 337, 339). Previous studies in 
recipients treated with inductive anti-CD4 mAb have revealed that repopulating CD4+ T 
cells are hyporesponsive toward donor antigen and mount Th2 responses upon re-
challenge, while naïve T cells mount a dominant Th1 response (297). In this CR model, 
alloreactive T cells only progress to a hyporesponsive state in response to TGFβ (Faust et 
al., submitted). The critical role for TGFβ in this CR model was revealed when CD4-
DNR mice were used as recipients and transiently depleted of CD4+ T cells. T cell TGFβ 
signaling was requisite for both long-term graft acceptance and suppression of graft-
reactive T and B cell responses as well as graft fibrosis (Faust et al., submitted). 
Therefore, systemic strategies targeting TGFβ are not feasible since this could alter the 
hyporesponsiveness of graft-reactive T and B cells.  In contrast, intragraft TGF 
inhibition would be beneficial in attenuating fibrosis. TGFβ neutralization within 




14). These findings demonstrate that localized TGFβ inhibition does not alter the 
systemic regulation of graft-reactive cells or lead to graft loss but was effective at 
reducing fibrosis associated with CR. 
 In transplantation, FoxP3+ Treg have been shown to play a central role in 
suppression of alloreactive T cells and in long-term allograft acceptance (reviewed in 
(270)). In both human and animal transplant, allograft acceptance strongly correlates with 
Treg infiltration into the graft as detected by enhanced intragraft FoxP3 transcript levels 
(138, 154, 354). Treg can be divided into two populations: natural Treg (nTreg), which 
arise in the thymus and do not require TGFβ to develop, and induced peripheral Treg 
(iTreg), which do require TGFβ to differentiate from naïve CD4+FoxP3- T cells into 
Treg (reviewed in (107)). In the current study, local neutralization of TGFβ did not affect 
intragraft FoxP3 expression, indicating that Treg migration and/or generation within the 
graft was unchanged between decorin and βgal transduced recipients (Figure 15D). 
However, these data argue against Treg induction within the grafts since intragraft 
TGFwas neutralized by decorin gene transfer. Indeed, Treg have been reported to be 
generated in lymph nodes and subsequently migrate to the graft (147). While thymic-
derived Treg do not require TGF for their generation, they do depend on TGF for their 
persistence in the periphery (133). Given that decorin gene transfer spares the systemic 
effects of TGF, it is also possible that nTreg may contribute in regulating alloreactive 
responses within the graft (373).  
Interstitial fibrosis represents a hallmark of CR and results in pathogenic cardiac 
remodeling and graft dysfunction (233). The effector cells in this process are cardiac 




that upregulate extracellular matrix synthesis and down-regulate matrix degradation 
(233). During remodeling, cardiac fibroblasts located within the interstitium proliferate 
and produce proteins such as collagen (234), resulting in a significant increase in 
interstitial fibrosis (374).  Cardiac fibrosis impairs contractility and reduces cardiac 
function.    
Previous studies demonstrate that decorin gene transfer ameliorates TGFβ-
induced fibrosis of multiple organs (196, 367). Decorin inhibits TGFβ bioactivity by 
sequestering TGFβ to the ECM (188, 193). In addition, decorin negatively impacts TGFβ 
gene expression by interrupting TGFβ/Smad-dependent transcriptional events (188, 193, 
195). One mechanism in which decorin inhibits fibrosis is by reducing TGFβ-induced 
collagen transcript levels in cultured human cardiac fibroblasts (197). Gene transfer of 
decorin into allografts transplanted into recipients transiently depleted of CD4+ T cells 
significantly attenuated collagen deposition and fibrosis compared to control allografts 
(Figure 16A and 16B).  Decorin over-expression also inhibited cardiac hypertrophy, 
demonstrating amelioration of an additional TGFβ-induced parameter correlated with CR 
(Figure 16C).  
In addition to reduced TGFβ gene expression, decorin reduced intragraft 
transcript levels IL-17 (Figure 15C).  IL-17 amplifies inflammatory responses (reviewed 
in (91, 93)) and has recently been identified as a cytokine with pro-fibrotic activities (92, 
331-334, 336). Prior studies in IL-17-/- recipients treated with anti-CD4 mAb revealed 
that allografts from the deficient mice exhibited a significant reduction in fibrosis 
compared to WT (Faust et al., submitted).  IL-17 may induce fibrosis though multiple 




been observed in mouse cardiac fibroblasts (92).  IL-17 may also induce endothelial cells 
and fibroblasts to secrete pro-inflammatory cytokines and chemokines (91, 97) that result 
in the recruitment of APC and alloreactive T cells into allograft. These inflammatory 
cells may secrete factors that lead to myocardial damage and tissue remodeling that 
favors fibrosis. The reduction of intragraft IL-17 expression in AdDec transduced grafts 
compared to WT counterparts further implicates this pro-inflammatory cytokine in CR.  
Decorin has multiple molecular targets in cell growth in addition to its interaction 
with TGFβ (184). Decorin negatively impacts cell proliferation, an effect mediated 
through the induction of p21 (184). Decorin-induced cell cycle arrest might reduce 
fibrosis by suppressing cardiac fibroblasts from proliferating and differentiating into 
myofibroblasts. Decorin also interacts with complement C1q, inhibiting activation of the 
classical complement pathway (186).  Hence, under inflammatory tissue damage and 
ECM remodeling, decorin may suppress complement activation and prevent further 
cardiomyocyte injury. Decorin may further inhibit the production of inflammatory 
chemokines and cytokines, including MCP-1 and IL-8 by preventing C1q from binding 
graft endothelial cells (186, 226). Therefore, in addition to decorin‟s inhibitory effects on 
TGFβ, suppression of complement activation may help to reduce fibrosis by limiting the 
damage inflicted on the allograft.                   
In summary, TGFβ is a critical cytokine in fibroproliferative disorders following 
inflammatory responses (reviewed in (342)). TGFβ can have both exacerbating and 
ameliorating effects in immune-mediated fibrotic diseases, making global inhibition 
undesirable and local neutralization of TGFβ an attractive therapy.  As evidenced in this 




et. al., submitted), while local TGF production at the site of inflammation induces graft 
fibrosis. We demonstrate that neutralizing intragraft TGFβ inhibits the cytokine‟s fibrotic 
activities, but does not reverse its beneficial immunosuppressive qualities.  These data 
provide insight into the underlying causes of CR, and identify intragraft TGF as a 




Chapter 5: Conclusion 
  
The Holy Grail of transplant tolerance, defined as a brief course of 
immunosuppression (induction), followed by indefinite acceptance of an allograft 
(maintenance), has yet to be achieved (375). Currently, the therapies used in the clinic to 
prolong graft survival globally suppress the immune response, require life long 
compliance, and are associated with a multitude of side effects, including increased risk 
of malignancies and infections (311). These therapies do not specifically target donor-
reactive cells and very often inhibit the induction of regulation, circumventing any 
development of tolerance induction (376). The failure to maintain tolerance leads to 
smoldering chronic inflammatory responses and may lead to CR (321). Therefore, while 
graft loss resulting from acute rejection is relatively rare due to immunosuppressive 
therapies, CR continues to challenge long-term graft survival and remains the primary 
cause of late graft failure.       
TGFβ has been strongly implicated as a mediator of both prolonged allograft 
acceptance, due to its anti-inflammatory effects, and the causative agent of 
fibroproliferative changes within the allograft associated with CR (232, 233, 342). We 
have previously reported an association with TGFβ and CR using the mouse vascularized 
cardiac allograft model (232). Transient depletion of recipient CD4+ T cells results in 
prolonged graft survival, intragraft expression of TGFβ, and the development of CR. In 




free of CR and fail to express intragraft TGFβ. Further, adenoviral-mediated gene transfer 
of the active form of TGFβ into allografts, but not syngeneic grafts, induced fibrosis and 
results in CR in recipients treated with anti-CD40L indicating that alloantigen is 
necessary for the progression of CR (232). Studies in this thesis focused on the role of T 
cell specific TGFβ signaling in CR, the contribution of IL-17 to graft fibrosis, and the 
effect of intragraft neutralization of TGFβ on systemic alloreactive responses and CR. 
5.1 Dissertation summary 
Experiments performed in Chapter 3 investigated the role of TGFβ signaling on 
alloreactive effector cells, Treg and IL-17 induction. We compared responses from WT 
and CD4-DNR recipients that were depleted of CD4+ T cells to responses from recipients 
that received anti-CD40L mAb therapy. In recipients treated with anti-CD40L mAb, T 
cell TGFβ signaling is not required for long term allograft acceptance. In contrast, 
prolonged allograft acceptance and suppression of alloreactive T and B cells responses 
require T cell TGFβ signaling in mice transiently depleted of CD4+ T cells. Further, IL-
17 is involved in the development of graft fibrosis and CR. 
Chapter 4 addressed the impact of local TGFβ neutralization by intragraft decorin 
gene transfer on donor-reactive T and B cell responses, cardiac hypertrophy and fibrosis. 
Intragraft neutralization of TGFβ significantly attenuated graft fibrosis and hypertrophy, 
improved graft function and failed to induce systemic donor-reactive T cell responses in 
recipients transiently depleted of CD4+ T cells. Thus, neutralizing TGFβ within the 
allograft inhibits the cytokine‟s pro-fibrotic effects, but does not reverse its anti-




Our finding that TGFβ in CR grafts correlates with compartmentalized IL-17 
production and participates in fibrosis is reminiscent of scleroderma, rheumatoid arthritis, 
allergic lung disease and hypersensitivity pneumonitis and lung fibrosis (231, 336, 351, 
377). In CR, as in most chronic inflammatory diseases, TGFβ can have both exacerbating 
and ameliorating actions. Hence, data reported here indicate the effectiveness of locally 
neutralizing TGFβ, or selectively targeting a downstream mediator, such as IL-17, as 
providing therapeutic targets for the prevention of fibrosis.  
5.2 Future directions 
 The data presented clearly associate TGFβ production with both allograft 
acceptance and CR in recipients transiently depleted of CD4+ T cells. Future directions in 
the CR model will include 1) identifying the cellular source of TGFβ; 2) elucidating the 
role of natural and induced Treg in controlling alloreactivity; 3) investigating the 
requirement for T cell-derived TGFβ in controlling donor-reactive cells and Treg 
development; and 4) determining if TGFβ-induced IL-17 is necessary and sufficient to 
induce fibrosis.  
TGFβ and the graft 
TGFβ is required for controlling alloreactivity and for inducing graft fibrosis in 
recipients transiently depleted of CD4+ T cells. The obvious question that remains is 
what cell type is generating this cytokine?  A variety of experimental organ transplant 
models indicate that the graft, rather than passively provoking an immunological 
rejection response has the ability to modulate its own survival through cytokine 
production (reviewed in (378)). A cardiac graft in a recipient transiently depleted of 




production. Indeed, both cardiomycoytes (379) and cardiac endothelial cells (380) are 
capable of generating TGF. Graft-derived TGF production may generate survival 
signals and/or modulate alloreactivity by playing a role in initiating and maintaining 
tolerance in the allogeneic transplant setting. To assess the graft‟s role in TGFβ 
production, mice that are both immunodeficient and TGFβ1 deficient will be employed as 
cardiac donor animals in our transplant model (381, 382). As mentioned previously, 
TGFβ1 null mice exhibit multifocal inflammation and autoimmune-mediated lethality by 
3 weeks of age (169). However, these animals can be rescued from the autoimmunity 
phenotype when crossed to SCID or RAG deficient mice (381, 383). Hence, these mice 
will provide a model to investigate the contribution of graft-derived TGFβ in CR.  
WT C57BL/6 mice (H-2
b
) will be transplanted with TGFβ1-/-SCID (H-2
d
) 
cardiac allografts and transiently depleted of CD4+ T cells (Figure 17). Graft function 
will be monitored and functioning allografts will be evaluated for signs of CR fifty days 
post-transplant. Prolonged allograft acceptance and evidence of CR would indicate that 
infiltrating immune cells generate TGFβ, and that the graft responds to this cytokine with 
fibroproliferative changes. In a rodent model of CR, TGFβ staining is detected on some 
infiltrating cells (primarily macrophages and lymphocytes) (384). Therefore, the 
enhanced expression of TGFβ within the allograft may represent an immunosuppressive 
mechanism mediated by immune cells to self-limit destruction either directly, by 
suppressing alloreactivity or, indirectly, by inducing immunosuppressive Treg within the 
graft (164). If prolonged allograft acceptance and no evidence of CR are observed, this 
would suggest that the graft generates TGFβ1 in response to inflammation, but that graft-




WT C57BL/6 mice (H-2
b
) will be transplanted 
with TGF1-/-SCID (H-2
d
) cardiac allografts and transiently depleted of CD4+ T cells. Graft 
function will be monitored and functioning allografts will be evaluated for evidence of CR fifty 
days post-transplants 
 
acceptance and a marked reduction in graft fibrosis would indicate a synergistic effect 
between graft-derived TGFβ and immune-mediated TGFβ in inducing fibrosis within the 
graft. Graft rejection would demonstrate that the graft plays an important role in early 
graft survival and tolerance induction by generating TGFβ. The graft may modulate the 
immune system through TGFβ1 production by inhibiting immune destruction and/or 
inducing the generation of Treg. A positive feedback loop may be established that 
involves the initial induction of Treg by graft-derived TGFβ, which is later augmented by 
TGFβ production by the Treg, themselves (143). These experiments will provide insight 
into the origin of TGFβ production and the effect of graft-derived TGFβ on prolonged 
allograft acceptance (143). 




Role of nTreg and iTreg in controlling alloreactivity 
In our model of CR, CD4+ Treg are postulated to be critical for the establishment 
of tolerance (297). Following transient depletion of CD4+ T cells, it is possible that 
nTreg are less susceptible to apoptosis or inactivation by anti-CD4 mAb. These 
regulatory cells may proliferate and accumulate within the graft and lymphoid tissue to 
maintain tolerance through TGFβ production (298). Indeed, Bromberg and colleagues 
recently reported that nTreg sequentially migrate into the allografts where these cells 
become activated and proliferate and subsequently proceed to the draining lymph nodes, 
where they suppress effector T cell proliferation and migration into the graft (373). In our 
mouse vascularized allograft study, as CD4+ T cells begin to repopulate the periphery 
and migrate into the graft or lymphoid tissues, these expanded nTreg may similarly 
suppress alloreactivity through TGFβ production, and in the absence of TGF signaling 
in T cells, allografts are rejected (Figure 18A).  
There may also be a role for iTreg in prolonged cardiac allograft acceptance 
following transient depletion of CD4+ T cells. As the CD4+ T cells begin to repopulate 
the periphery, the healed-in allograft will continue to release antigens that are processed 
by the host APCs in a non-inflammatory environment (305). In the absence of 
inflammatory danger signals, quiescent APC may present alloantigen and generate TGFβ, 
resulting in the expansion of iTreg and suppression of alloreactive cells (Figure 18B) 
(262). Indeed, persistent incomplete signaling of T cells by alloantigen and TGFβ 
production can drive CD4+ T cells to become both anergic and regulatory (138, 262, 
298). The iTreg may sustain and recruit additional iTreg through TGFβ production and 



























































(A) Allograft acceptance in recipients transiently depleted of CD4+ T cells requires T cell 
responsiveness to TGF. In the absence of T cell TGF signaling, graft-reactive effector cells 
induce allograft rejection. (B) As the CD4+ T cells begin repopulating the periphery, the healed-




in graft will continue to release antigens that are processed by the host APCs in a non-
inflammatory environment. In the absence of inflammatory danger signals, quiescent APC may 
present alloantigen and generate TGF, resulting in the expansion of iTreg and suppression of 
alloreactive cells. (C) As repopulating CD4+ T cells migrate into the graft or lymphoid tissues, 
Treg may suppress alloreactive responses through TGF production.  
 
induction of naïve CD4+CD25- T cells into Tregs both in vivo and in vitro argues for the 
importance of this cytokine in the generation and maintenance of the peripheral Treg pool 
(138). 
To investigate the contribution of natural and induced Treg in allograft acceptance 
in recipients transiently depleted of T cells in vivo, cardiac transplants will be performed 
in monospecific TCR-transgenic mice to determine the ability of inductive anti-CD4 
mAb to induce de novo Treg. Female transgenic mice will be employed which generate 
CD4+ T cells that are monospecific for the male transplantation antigen  Dby (presented 
by H-2E
k
) on a RAG-/- background (A1(M).RAG-/-) (340). Dby encodes a dead box 
RNA helicase Y protein involved in diverse cellular functions, including RNA splicing, 
ribosomal assembly and protein translation (385). The Dby gene generates two 
transcripts: a long transcript that is ubiquitously expressed and a short transcript that is 
testes specific. The protein derived from the long Dby transcript is a class II restricted 
antigen and is highly expressed in cardiac tissue (340, 385).  These mice have no 
prexisiting FoxP3+ Treg in the thymus or periphery (129, 340, 386) and are capable of 
rejecting a male skin graft acutely, within 15-20 days post-transplant (138).  
Female A1(M).RAG-/- transgenic mice will be transplanted with male 
CBA.RAG-/- or female CBA.RAG-/- cardiac allografts and transiently depleted of CD4+ 
T cells (Figure 19). Graft function will be monitored and recipients with functioning 




 Female A1(M).RAG-/- transgenic mice that are monospecific for the male transplantation 
antigen Dby presented by H-2E
k
 on a RAG-/- background will be transplanted with a male or 
female allograft from CBA.RAG-/- donors and transiently depleted of CD4+ T cells. The Dby 
protein is a class II restricted antigen and is highly expressed in cardiac tissue. iTreg generation 
will be assessed by quantitative RT-PCR to assay for intragraft FoxP3 expression and by flow 
cytometry to quantify the percent of FoxP3+CD25+CD4+ GICs and splenocytes. 
 
generation will be assessed by quantitative RT-PCR to assay for intragraft FoxP3 
expression and by flow cytometry to quantify the percentage of FoxP3+CD25+CD4+ 
GICs and splenocytes. It is predicted that prolonged allograft acceptance will be observed 
in recipients of both male and female cardiac grafts. However, Treg will only be detected 
in recipients of male CBA.RAG-/- cardiac allografts. This will strongly support the 
hypothesis that FoxP3 expressing Treg can be induced in the periphery from naïve 
CD4+FoxP3- T cells following anti-CD4 mAb treatment. Alternatively, rejection of 
allografts will indicate that nTreg, or a synergistic relationship between nTreg and iTreg, 
are critical for prolonged allograft acceptance in anti-CD4 mAb treated recipients.  




iTreg and infectious tolerance 
Tolerant animals can maintain their grafts following adoptive transfer of naïve 
cells, and this is referred to as the acquisition of resistance, or infectious tolerance (238). 
Previous studies in our lab have investigated the ability of WT recipients treated with 
anti-CD4 mAb to maintain prolonged allograft acceptance following adoptive transfer of 
naïve splenocytes or splenocytes isolated from day 7 unmodified WT recipients, which 
will be referred to as effector T cells. Under both experimental conditions, prolonged 
allograft acceptance is observed, when cells are transferred to primary graft recipients on 
day 30 post-transplant. These data indicate an antigen specific regulation and 
maintenance of peripheral tolerance in the transplant setting. It is unknown, however, 
whether the adoptively transferred splenocytes undergo apoptosis or anergy, and/or 
whether a subset is induced in the periphery to become Treg, themselves.   
To assay for iTreg induction of T cells following adoptive transfer in a fully MHC 
mismatched setting, WT C57BL/6 mice will be transplanted with BALB/c allografts and 
transiently depleted of CD4+ T cells. Allograft recipients will be infused with 
CD4+CD25-FoxP3- naïve T cells or CD4+CD25-FoxP3- effector T cells from 
FoxP3GFP transgenic mice (Figure 20). FoxP3GFP transgenic mice express an enhanced 
green fluorescent protein under the control of the mouse Foxp3 promoter (387). In order 
to track the transferred cells and verify that the cells survive, the cells will be labeled with 
a 675 nm-emitting proliferation dye (CellVue Claret). Graft function will be monitored 
and recipients with functioning grafts at day 50 post-transplant will be evaluated for 
peripheral Treg induction by quantitative RT-PCR to assay for intragraft GFP expression 






WT C57BL/6 mice will be transplanted with 
BALB/c allografts and transiently depleted of CD4+ T cells. On day 30 post-transplant, recipients 
will receive CD4+CD25-FoxP3- naïve T cells or CD4+CD25-FoxP3- effector cells from 
FoxP3GFP transgenic mice. Graft function will be monitored and recipients with functioning 
allografts at day 50 will be evaluated for peripheral Treg induction by quantitative RT-PCR to 
assay for intragraft GFP expression and by flow cytometry to quantify the percentage of 
GFP+CD4+CD25+ GICs and splenocytes. 
 
splenocytes. It is predicted that adoptive transfer of WT recipients with either naïve or 
effector CD4+ T cells from FoxP3GFP transgenic mice will result in prolonged allograft 
acceptance as observed in WT recipients. The detection of GFP+CD4+ T cells within the 
graft or spleen of primary graft recipients will indicate the de novo generation of 
potentially immunoregulatory T cells in vivo. These experiments will provide insight into 
the role of Treg in the maintenance of transplant tolerance in recipients transiently 
depleted of CD4+ T cells. 
 




T cell-derived TGFβ and allograft acceptance 
The requirement for T cell TGFβ signaling in controlling alloreactivity in 
recipients transiently depleted of CD4+ T cells was demonstrated in CD4-DNR mice 
(Chapter 3). Abrogation of T cell TGFβ signaling in this model results in donor-reactive 
Th1 and Th2, a significant reduction in Treg accumulation within the grafts and graft 
rejection dependent on CD4+ T cell population. Hence, TGFβ is crucial for regulation of 
T cell proliferation and survival, inhibition of Th1/Th2 differentiation and in Treg 
generation/maintenance in this model of transplant. However, it is unclear whether T cell-
derived TGFβ or TGFβ produced by other cells within the environment is important for 
modulating alloreactivity and allograft fibrosis. Hence, experiments in this section will 
identify whether T cell generated TGFβ is required for allograft fibrosis and for 
controlling systemic immune responses in the transplant setting. 
 Studies conducted in TGFβ deficient mice have provided insight into the 
requirement for TGFβ in Treg maintenance and for suppressor function (124). Employing 
the TGFβ null mouse model, it was demonstrated that this cytokine is not required for the 
development of nTreg but is important for iTreg generation and maintenance of 
peripheral Treg. This was evident in that the TGFβ null mice exhibit normal thymic Treg 
numbers but a decline in the peripheral Treg population (124). Additional support for the 
role of TGFβ in peripheral Treg maintenance was provided in experiments performed in 
WT mice that received systemic neutralization of TGFβ by anti-TGFβ Ab administration 
(124). A dramatic decline in the number of peripheral Treg that was comparable to what 
is seen in TGFβ null mice was observed, corroborating the role of TGFβ in peripheral 




suppress colitis in an adoptive transfer model in which the recipients express TGFβ (124, 
356). This indicates that TGFβ produced by neighboring cells can sustain Treg 
suppressor function and phenotype, and that Treg may induce TGFβ expression from 
APCs or stromathymal and mesenchymal cells (388). Indeed, TGFβ -/- Treg combined 
with TGFβ -/- APCs are no longer capable of suppressor function, which is consistent 
with a requirement for exogenously supplied TGFβ1 to sustain the regulatory phenotype 
(124). 
To assay for the requirement of T cell-derived TGFβ or TGFβ produced by non-T 
cells in prolonged allograft acceptance, T cell specific TGFβ null mice (389) will be 
employed as transplant recipients and transiently depleted of CD4+ T cells (Figure 21). 
These mice have a conditional knockout allele for TGFβ in which exon 6 of the gene is 
flanked with LoxP sites. When crossed to LCKCre transgenic mice, a T cell specific 
disruption of TGFβ is generated (389). T cell specific deletion of TGFβ does result in 
increased organ inflammation and Th1-effector cytokine production in the mice, but this 
phenotype is predominantly seen in older mice (5 months), permitting the use of this 
model in transplant experiments (389). Graft function will be monitored and functioning 
allografts will be evaluated for signs of CR fifty days post-transplant. ELISPOT will be 
employed to quantify donor-reactive Th1, Th2 and Th17 responses. Treg will be assessed 
by quantitative RT-PCR to assay for intragraft FoxP3 expression and by flow cytometry 
to quantify the percentage of FoxP3+CD25+CD4+ GICs and splenocytes. CR (as 
assessed by graft fibrosis) and prolonged allograft acceptance would indicate that non-T 
cell derived TGF is sufficient for fibrosis and allograft acceptance. Reduced CR and 





T cell specific TGF 
null mice (H-2
b
) will be employed as transplant recipients and transiently depleted of CD4+ T 
cells. Graft function will be monitored and functioning allografts will be evaluated for signs of 
CR fifty days post-transplant. ELISPOT will be employed to quantify donor-reactive Th1, Th2 
and Th17 responses. Treg will be assessed by quantitative RT-PCR to assay for intragraft FoxP3 
expression and by flow cytometry to quantify the percentage of FoxP3+CD25+CD4+ GICs and 
splenocytes. 
 
is required for fibrosis and that non-T cell derived TGF is required for allograft 
acceptance. Prolonged allograft survival and no evidence of fibrosis would indicate that T 
cell derived TGF is required for fibrosis and that non-T cell derived TGF is sufficient 
for allograft acceptance. Finally, allograft rejection would indicate the requirement for T 
cell derived TGF in allograft acceptance. 




TGFβ, IL-17 and CR 
IL-17 is a pro-inflammatory cytokine with pleotropic functions that has been 
implicated in the development and progression of various autoimmune diseases 
(reviewed in (377)). Data presented in this dissertation implicate TGFβ-induced IL-17 as 
a mediator of graft fibrosis in recipients transiently depleted of CD4+ T cells. In chapter 
3, IL-17 deficient recipients treated with anti-CD4 mAb exhibited a significant reduction 
in graft fibrosis compared to WT counterparts. In chapter 4, localized TGFβ 
neutralization by decorin gene transfer reduced intragraft IL-17 expression and fibrosis. 
Additional experiments will investigate whether IL-17 expression is both necessary and 
sufficient to induce graft fibrosis.  
WT cardiac recipients transiently depleted of CD4+ T cells exhibit a 
compartmentalized Th17 response within the allograft. Th17 polarization within target 
tissue has also been observed in murine models of allergic lung disease and 
hypersentitivity pneumonitis and lung fibrosis (336, 350). This may indicate that, in 
response to the inflammatory milieu, Th17 cells are generated directly at the site of 
inflammation or within draining lymph nodes. Veldhoen and colleagues demonstrated 
that naïve CD4+ T cells could differentiate into Th17 cells in the presence of DC-derived 
IL-6 and Treg generated TGFβ (326). In the absence of Treg, the cells committed to a 
Th1 phenotype. This was corroborated by a number of researchers, including Bettelli et. 
al., who showed that naïve CD4+ T cells activated by anti-CD3 in the presence of TGFβ 
leads to the production of Treg, but that activation in the presence of IL-6 in addition to 
TGFβ diverted the naïve cells to develop into Th17 (93). Similar findings were reported 




mature or immature BMDCs in the presence of Treg, enhanced, rather than suppressed, 
IL-17 production in the course of an alloreactive response through the production of 
TGF (271). DC-derived IL-6 in conjunction with Treg produced TGF were necessary 
and sufficient to drive Th17 development. This occurred simultaneously while Treg 
inhibited Th1 and Th2 differentiation through a TGF dependent mechanism (271).  
The mechanism by which Th17 develop and induce fibrosis in cardiac allografts 
remains to be elucidated. CD4+ activated effector and memory T cells have been 
identified as the cell type that primarily secrete IL-17 (97). However, recent reports 
indicate that non-immune cells, such as cardiac fibroblasts, can express significant 
quantities of IL-17 (92). The functional IL-17 receptor (IL-17R) is a heteromeric 
complex of IL-17RA and IL-17RC (390). The IL-17R is present on a variety of cell 
types, including human and mouse cardiac fibroblasts (CF), which express both IL-17RA 
and IL-17RC. In addition, in cardiac fibroblasts, the IL-17R is upregulated in response to 
IL-17 (92).  
Experiments in IL-17 deficient recipients that received WT BALB/c allografts 
and were transiently depleted of CD4+ T cells indicate that the cells primarily responsible 
for secreting IL-17 are immune cells, most likely CD4+ T cells. It is postulated that the 
polarized Th17 response is generated either within the cardiac allograft or in the draining 
lymph nodes (dLN), and that TGFβ-producing Treg accumulate within the grafts and/or 
lymph nodes and enhance the Th17 lineage development (271, 373). It may also be 
possible that a population of IL-17 secreting Treg are the mediators of IL-17 production 
(391). It has recently been reported that mouse FoxP3+CD25+ Treg can be converted 




response to IL-23 signals from DCs (391). Therefore, Treg may play an unexpected pro-
inflammatory role, depending on signals from innate cells. To investigate Th17 priming 
within the allografts and dLN, intracellular cytokine staining will be performed on GICs 
or T cells isolated from the dLN to examine IL-17, FoxP3, and CD4 expression in WT 
and IL-17 deficient recipients transiently depleted of CD4+ T cells. Allografts and dLNs 
will be recovered on day 30 post-transplant, since transient priming of alloreactive cells 
peaks at this time (297). It is predicted that a discrete population of IL-17 producing 
CD4+ T cells will be observed in the allografts and/or dLNs of WT recipients and that 
these are the cells responsible for inducing fibrotic changes associated with CR. IL-17 
may induce myocardial inflammation, injury and tissue remodeling through a number of 
mechanisms and may act synergistically with TGFβ to induce cardiac fibrosis (Figure 
22). Among its many functions, IL-17 stimulates matrix metalloproteinase 1 (MMP-1) 
expression and secretion in primary human CF through the activation of p38 MAPK- and 
ERK1/2-dependent c/EBP, NF-B and AP-1 (331). In the myocardium, MMPs degrade 
ECM and release and activate ECM-bound factors, like TGFβ. Activated TGFβ can 
induce cardiac fibroblasts to generate and remodel ECM (233) and TGFβ induced Smad 
signaling has been reported to negatively regulate MMP expression by sequestering AP-1 
proteins to the cytoplasm (392). This feedback loop ensures that during normal tissue 
remodeling, the rate of synthesis of ECM proteins is balanced by ECM degradation 
(342). However, excessive TGFβ production upsets this balance and leads to fibrosis 
(342). Indeed, diminished myocardial MMP activity can directly facilitate collagen 







Treg play a critical role in allograft acceptance by 
inhibiting donor-reactive Th1 and Th2 responses and by inducing additional Treg from naïve 
CD4+ T cells in a TGF-dependent mechanism. However, recent in vitro studies have 
demonstrated that Treg do not suppress, but rather enhance IL-17 production in the course of an 
alloreactive response. Benghiat and colleagues demonstrate that when DCs are used as allogeneic 
stimulators, Tregs are critically required for driving IL-17 production in CD4+CD25- T cells. 
Further, Treg derived TGF and IL-6 generated by DCs act to synergistically induce alloreactive 
CD4+ T cells to produce IL-17. IL-17 may induce fibrosis through multiple mechanisms. IL-17 
may act as a potent pro-inflammatory cytokine that induces endothelial cells and fibroblasts to 
secrete additional pro-inflammatory cytokines, such as IL-6 and TNF. These factors may 
enhance the recruitment of APC and alloreactive T cells into the graft resulting in myocardial 
damage and ECM remodeling that favors fibrosis. IL-17 can also act directly on cardiac 
fibroblasts by upregulating MMP expression through NF-B, c/EBP and AP-1 activation. 
MMPs are activated during inflammation. In addition to ECM degradation, MMP degrades the 
latency associated peptide and releases active TGF. TGF is then free to upregulate its 
downstream mediator, CTGF. CTGF in association with a mitogenic stimulus, PDGF, stimulates 
cardiac fibroblasts to proliferate. Further association with IGF-2 results in differentiation of 
fibroblasts into myofibroblasts, which upregulate collagen synthesis. Persistence of these 
myofibroblasts leads to fibrosis. 
 




In addition to activating TGFβ, IL-17 induces primary CF migration in an MMP-
1-dependent manner. Fibroblast migration and proliferation are two critical steps in 
cardiac fibrosis (233) and IL-17 may contribute to fibrosis through this mechanism. 
Finally, IL-17 has been reported to directly stimulate collagen and other ECM production 
in CF and may play a role in cardiac fibrosis and remodeling through this mechanism 
(92). 
Only recently has IL-17 been identified as a pro-fibrotic cytokine. This Th17 
cytokine is best recognized for its pro-inflammatory functions and can promote chronic 
tissue inflammation (91, 97, 98, 377). IL-17 upregulates NF-B, AP-1 and c/EBP1/2 
responsive pro-inflammatory cytokines, chemokines, and adhesion molecules in the heart 
(331). Th17 promote tissue inflammation and chronic inflammatory diseases (393). In a 
CR allograft, IL-17 may upregulate and synergize with the pro-inflammatory cytokines, 
IL-6 and TNF, to induce inflammation and injury to the myocardium (294). Therefore, 
IL-17 has the potential to directly impact cardiac remodeling through its effects on TGFβ, 
collagen, MMPs, and tissue remodeling and/or may generate myocardial injury by 
inducing pro-inflammatory cytokines and chemokines that attract inflammatory cells to 
the allograft.                                  
While it is clear that IL-17 plays a critical role in graft fibrosis, it remains to be 
elucidated whether this cytokine is both necessary and sufficient to initiate these 
fibroproliferative changes. In collaboration with Dr. Joseph Rabinowitz at Thomas 
Jefferson University, a recombinant Adeno-associated virus serotype 6 vector (AAV6) 




recently been demonstrated to provide stable, long-term expression of transgenes that are 
capable of reversing heart failure in a rodent model (394).  
Preliminary cardiac perfusion studies with the AAV6-IL-17A vector in the mouse 
vascularized allograft model indicates robust transgene and protein expression as early as 
day 7 with increasing transgene expression over the experimental period of 50 days. In 
order to identify whether IL-17 is both necessary and sufficient to induce fibrotic changes 
associated with CR, BALB/c allografts will be perfused with the AAV6-IL17A vector 
prior to transplant into IL-17 deficient recipients transiently depleted of CD4+ T cells or 
WT recipients treated with inductive anti-CD40L mAb therapy (Figure 23). It is 
predicted that this strategy should rescue the CR phenotype in recipients if IL-17 is the 
BALB/c allografts will be perfused with rAAV6-IL-17A prior to transplant into IL-17 deficient 
recipients transiently depleted of CD4+ T cells or WT recipients treated with inductive anti-
CD40L mAb. Graft function will be monitored and functioning allografts will be evaluated for 
evidence of CR fifty days post-transplant. 
 




causative agent of graft fibrosis. However, we may demonstrate that IL-17 is neccesary 
but not sufficient to sustain fibrosis. Additional IL-6 neutralization experiments will be 
performed with this vector to investigate the requirement for both IL-6 and IL-17 in CR, 
since IL-6 has been identified as a contributing cytokine in both fibrosis and cardiac 
hypertrophy in CR (294). These experiments will reveal the sufficiency of IL-17 in graft 
fibrosis and further characterize the role IL-17 plays in CR.   
5.3 Concluding remarks 
Organ transplantation is one of the most significant therapeutic advancements 
made in the second half of the 20
th
 century. Research in the transplant field has revealed 
the most basic tenets of immunology: the discovery and characterization of the MHC, 
immunological self-tolerance, the requirement for TCR activation and co-stimulation, 
inflammatory „danger‟ signals, Treg, effector and memory cell development and 
function. Knowledge gained in studying the immune response toward the transplanted 
organ has deepened our understanding of the immune system in health and in disease and 
has given us a model to harness immunological self-tolerance. The data herein has 
provided two therapeutic targets that can potentially be neutralized locally within the 
allograft to suppress the progression of CR: TGFβ and IL-17. Additionally, it is clear that 
there are TGFβ-dependent and -independent mechanisms of allograft acceptance. Hence, 
it is possible that therapies that rely on the immunosuppressive activities of TGFβ to 
control alloreactive responses may have the undesired effect of generating T cell 
dependent graft fibrosis. In conclusion, a vast quantity of experimental data exists that 
transplant tolerance can be achieved. Perhaps one of the most significant therapeutic 
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